



**MADRID, SPAIN**

## Advancing Community Health and Well-being by Addressing Inequity in the Practice of Medicine

**October 6, 2022**

Hotel Riu Plaza España  
C/ Gran Via, 84 - 28013  
Madrid, Spain

Jointly provided by:

Healthfirst, SOMOS Community Care, and Albert Einstein College of Medicine — Montefiore Medical Center



**Montefiore**



# Advancing Community Health and Well-being by Addressing Inequity in the Practice of Medicine

Andrey Ostrovsky, MD, FAAP  
Managing Partner | Social Innovation Ventures  
Former US Medicaid Chief Medical Officer  
@andreyostrovsky

October 6, 2022



Social Innovation Ventures



## Disclosures /

No conflicts of interest to report. I do have a financial interest in the following companies: <https://www.socialinnovationventures.co/>



## Objectives /

1. Understand what social deprivation indices measures
2. Recognize the role of primary care in addressing social risk factors
3. Know about state models in Medicare and Medicaid that provide align financial incentives with addressing social risk
4. Learn about a service design technique to bring diverse stakeholders together to redesign care models toward health equity

*The workshop convenings have been made possible through generous support from The Commonwealth Fund, a national, private foundation based in New York City that supports independent research on health care issues and makes grants to improve health care practice and policy, and Arnold Ventures, a philanthropy dedicated to tackling some of the most pressing problems in the United States through research, education, and advocacy. The views presented here are those of the author and not necessarily those of The Commonwealth Fund and Arnold Ventures, its directors, officers, or staff. Additional support has been provided by the American Board of Medicine Foundation, 3M Health Information Systems, and the Samueli Foundation.*



/ Medicare Workshop Summary

# / Medicare Workshop Overview

## Facilitators

/ Medicare Workshop Summary



**Andrey Ostrovsky,**  
MD, FAAP  
Former U.S. Medicaid  
Chief Medical Officer



**Bob Phillips,**  
MD, MSPH  
ABFM



**Andrew Bazemore,**  
MD, MPH  
ABFM



/ Medicare Workshop Summary

## Workshop Overview /

On March 31, 2022, **18** federal & Industry experts gathered at the Cosmos Club in Washington, DC, to discuss the future state of incorporating social risk factors into Medicare Advantage (MA) payment adjustments. Specifically, the group discussed operational pathways that would ensure social risk-based payments address social needs rather than increasing profit margins for health insurers.



/ Medicare Workshop Summary

## Workshop Plan /

The group was tasked with creating the ideal risk payment adjustment scenario (future-state) across three swimlanes to address the beneficiary's needs:

**Provider**

**Medicare Advantage MCO**

**Center for Medicare**





/ Medicare Workshop Summary

## Scenario /

### Ms. Koval

Elderly dual -eligible widow with three chronic health conditions, living in a poor neighborhood struggling to manage healthy meals, transportation, and care coordination	Primary care is part of a health care system that is geographically spread out, so misses appointments, falls behind in chronic care management. Lack of assessment and support and becomes more frail	Multiple falls lead to repeat Emergency Department visits and hospitalizations with no discharge transition support	Worsening frailty and quality of life  Very high, unnecessary costs  Lack of tap of existing community support (aging services, meals on wheels)  More likely to be placed in a nursing home
--	--	---	--

/ Medicare Workshop Summary

# / Findings & Recommendations



/ Medicare Workshop Summary

### Finding 1

Patients often do not trust insurers or the healthcare system.

/ Medicare Workshop Summary

### Recommendation /

To build trust, there should be an effort to build a personal relationship in conjunction with visits. Additionally, clinicians should work with CBOs as a "trust bridge" so that patients can feel comfortable providing the appropriate information to enable clinicians to address social needs.





/ Medicare Workshop Summary

## Finding 2

Providers should adapt their practice to address social needs directly or in partnership with community based organizations (CBOs).

/ Medicare Workshop Summary

### **Recommendation /**

Clinical practices (typically PCPs, but in some cases specialists) should invest in new staff that are non-clinicians to assist with care coordination and possibly social service provision.







### Finding 3

Beneficiary -specific social need data are difficult to obtain and maintain for the most disadvantaged populations. There is an ethical obligation to address identified social needs; collecting the data is a burden and the inability to address social needs is a source of burnout.

### **Recommendation /**

People share personal needs when they see its value and have trust. Allow the beneficiary, as well as the caregiver, to choose who they trust.





/ Medicare Workshop Summary

#### Finding 4

MA plans should fund medical and non -  
medical providers to enable them to  
address social needs.

/ Medicare Workshop Summary

#### **Recommendation /**

To support clinicians in serving social needs, Medicare may provide a transportation benefit, broaden the post-discharge home visit waiver, and use telehealth more robustly and on a permanent basis.






### Finding 5

Payment adjustment for social risk should be based a curvilinear relationship rather than thresholds.

### **Recommendation /**

Payment adjustment should rise as social risk increases based on small-area social deprivation indices.





/ Medicare Workshop Summary

## Finding 6

Accountability means resources flow through primary care and CBOs to the patient and community.

/ Medicare Workshop Summary

## **Recommendation** /

There needs to be just enough accountability without overburdening clinicians or community-based partners.





/ Medicare Workshop Summary

# / Medicaid Workshop Overview

WORKSHOP OVERVIEW /

## Defining Future State to Account for Social Risks in Medicaid Payments

American Board of Family Medicine Foundation /



Social Innovation Ventures





/ Medicaid Workshop Summary

## Workshop Overview /

On May 12, 2022, 22 federal & Industry experts gathered at the Cosmos Club in Washington, DC, to discuss the future state of incorporating social risk factors into Medicaid payment adjustments. Specifically, the group discussed operational pathways that would ensure social risk-based payments address social needs rather than increasing profit margins for health insurers.



/ Medicaid Workshop Summary

## Workshop Plan /

The group was tasked with creating the ideal risk payment adjustment scenario (future-state) across three swimlanes to address the beneficiary's needs:

### Provider (Care Team)

---

Medicaid - Managed Care Organization

---

State Medicaid

---





/ Medicaid Workshop Summary

## Scenario 1 /

### Ms. Koval

Elderly dual -eligible widow with three chronic health conditions, living in a poor neighborhood struggling to manage healthy meals, transportation, and care coordination	Primary care is part of a health care system that is geographically spread out, so misses appointments, falls behind in chronic care management. Lack of assessment and support and becomes more frail	Multiple falls lead to repeat Emergency Department visits and hospitalizations with no discharge transition support	Worsening frailty and quality of life  Very high, unnecessary costs  Lack of tap of existing community support (aging services, meals on wheels)  More likely to be placed in a nursing home
--	--	---	--

/ Medicaid Workshop Summary

## Scenario 2 /

### Parker Family

Rural, poor family distant from health care and social services and without broadband  Must drive 90 miles to reach nearest clinic	Breaks in Medicaid coverage  Lack of developmental tracking and preventive care  Lack of WIC, SNAP	Rural Health Clinic loses its Critical Access Hospital partner (loss of cost -based reimbursement and support for social workers, behavioral health, etc.)  Telehealth/Tele -social services not able to fill gaps	Poor health outcomes  Prolonged hunger  Poor educational attainment  Poverty cycle reinforced  Higher downstream costs
--	--	--	--



/ Medicaid Workshop Summary

# / Findings & Recommendations

/ Medicaid Workshop Summary

## Finding 1

**Payment adjustment for social risk factors should be based on both community and individual variables.**





/ Medicaid Workshop Summary

### Recommendation /

Small-area deprivation indices should be used for adjusting payments because they reduce burden of data collection, have low potential for gaming, and offer transparency for payers and providers.



/ Medicaid Workshop Summary

### Finding 2


**The Maryland and Massachusetts Models offer templates for how to design social risk -adjusted payments that can meet the varied needs of different state Medicaid programs.**



/ Medicaid Workshop Summary

### Recommendation /


SMA should update their state plans to classify SDOH services as medical assistance thus qualifying them for federal match. Medicaid MCOs or non-MCO payment distribution entities should update their credentialing processes to include SDOH providers as being in-network and eligible to receive SDOH payments.



/ Medicaid Workshop Summary

### Recommendation /

Medicaid MCOs or non-MCO payment distribution entities should apply their network management approaches to SDOH providers to ensure only high-quality providers are reimbursed for care.






/ Medicaid Workshop Summary

### Recommendation /

SDOH providers should be able to easily access funds.

Prospective payment can improve ease of accessing those funds.



/ Medicaid Workshop Summary

### Finding 3

**Community involvement is essential for social risk -adjusted payments to be implemented equitably and effectively. These payments can help fill in gaps in CBO infrastructure.**



/ Medicaid Workshop Summary

### Recommendation /

Patient representation is needed at all levels of policy design, implementation, and evaluation pertaining to payment risk adjustment for social risk. Social risk-adjusted payments can help fill in gaps in CBO infrastructure that will shore up the community safety net.



/ Medicaid Workshop Summary

### Finding 4

**Patients and families need help navigating services. Providers need help navigating among themselves and health and human service agencies.**



/ Medicaid Workshop Summary

### Recommendation /

The SMA should coordinate with other health and human service agencies and/or the SMA should provide resources to fund navigators, brokers, or managed service organizations (MSOs) that help providers coordinate amongst themselves and with other health and human service stakeholders at the local, state, and federal level.



/ Medicaid Workshop Summary

### Recommendation /

CBOs may need support with payment processing, reporting, and practice transformation and this role could be filled by MSOs specific to CBOs. Maryland's Care Transformation Organization (CTO) model can serve as a template.





/ Medicaid Workshop Summary

### Finding 5

**Data interoperability must be improved if SDOH payment adjustments are to lead to effective care coordination and improved health.**

/ Medicaid Workshop Summary

### **Recommendation /**

Improvements to data sharing should be attempted through the least regulatory burdensome routes possible, starting with existing authorities before seeking new regulation or legislation. There is an ethical obligation to be able to address individual gaps in SDOH if those gaps are being screened for.





/ Medicaid Workshop Summary

## Finding 6

**Telehealth plays a major role in equitably improving outcomes and should be covered and reimbursed permanently.**

/ Medicaid Workshop Summary

## **Recommendation /**

Permanent coverage and reimbursement for telehealth should be attempted through the least regulatory burdensome routes possible, starting with existing authorities before seeking new regulation or legislation.





/ Medicaid Workshop Summary

### Finding 7

Payment for social risk should be included in the MLR, would achieve better outcomes in value based payment arrangements compared to fee -for -service (FFS), and should be measured through the lens of improved outcomes rather than just cost savings.

/ Medicaid Workshop Summary

### Recommendation /

CMCS and SMAs should allow Medicaid MCOs to incorporate payments for SDOH services into the MLR, then assess the degree of impact.

In subsequent years, the premium amount can be increased if SMAs see that there are improved outcomes and cost-containment or reduction.







/ Medicaid Workshop Summary

### Finding 8

**Measurement and evaluation of use of funds should not be overly burdensome to providers and should focus more on outcomes than on process, although process measures are likely still needed.**

/ Medicaid Workshop Summary

### **Recommendation /**

Accountability for the SDOH provider can be achieved through **1)** attestation of how funds were used (process measure), **2)** measurement of concrete clinical outcomes such as reduction in emergency room utilization and Quality-adjusted Life Years (QALYs)...





/ Medicaid Workshop Summary

### Recommendation /

and 3) approval/disapproval of further funding based on presentation to a “council of grandmas,” a group representative of patients with substantial financial power over direction of dollars for providers.



/ Medicaid Workshop Summary

### Recommendation /

Feedback from patients, SDOH providers, Medicaid MCOs, and SMAs would shape how CMCS evolves social risk factor adjustment into payment moving forward. Health equity should be incorporated into the goals and evaluation value-based contracts.





*/ Questions*

*/ Thank you!*

@andreyostrovsky



# The Changing Environment of Healthcare: A Look at Evolving Primary and Ambulatory Care

Arthur Klein, MD, BSMD

Previous President and Previous President Emeritus of the Mount Sinai Health Network  
Clinical Professor of Pediatrics and Administration at the New York Institute of Technology  
Adjunct Professor, Mailman School of Public Health, Columbia University

October 6, 2022

## Purpose and Objectives

### PURPOSE

*To examine the changing environment of healthcare through evolving primary and ambulatory care*

### OBJECTIVES

- *Objective 1:* To gain knowledge about the current challenges and anticipated changes in the healthcare environment
- *Objective 2:* To learn about what is attractive about the ambulatory arena

### FINANCIAL DISCLOSURE

*None*



## Current Trends in Healthcare in the US

1. Consolidation in the industry
  - Insurance companies
  - Hospitals
  - Physicians
2. Migration of care to the ambulatory environment
3. Virtual care/telemedicine
4. The move to population health
5. Consumerism

## Current Trends in Healthcare in the US

6. The prevalence of chronic diseases
  - Diabetes, asthma, obesity, cancer
  - Diseases of aging (Alzheimer's, Parkinson's)
7. Addressing healthcare inequities
8. Increasing reliance on technology
9. Ever increasing healthcare costs
10. The emergence of concierge medicine



## Current Challenges

1. Socioeconomic factors and their impact on healthcare
2. An aging population
3. Critical increases in healthcare expenditures
  - What are we getting for the cost of healthcare in the US compared to other western economies?
4. Workforce issues
  - Not enough? Disenfranchised? Not the right specialties?
5. The migration of healthcare to the ambulatory environment
6. The expectations of increasing consumerism in healthcare

## Current Challenges

7. The continued lack of insurance coverage for a large group of Americans
8. How to incorporate and pay for new technologies
9. Lack of a public health structure
10. The burdens of chronic disease
11. How to restructure the academic medicine enterprise in the US to be more responsive to the changing education and training needs of medical professionals.



## Why Ambulatory Care?

1. More cost-effective: operating costs, capital costs
2. Allows for greater geographic spread of healthcare services
3. More efficient: witness ambulatory surgery
4. Speed to market
5. More responsive to consumerism: convenience, ambience, services
6. Allows for less complex “once stop shopping” for patients (multi-specialty groups)

## Why Ambulatory Care?

7. Creates new investment opportunities without upsetting the financial structure of the hospitals.
8. Allows for enhanced physician alignment
9. Payer pressure
10. Is vital if we are to extend our commitment to public health and preventative medicine
11. Takes the pressure off acute care hospitals in medical emergencies (witness COVID)
12. Provides an environment for rapidly adopting new technologies



## Ambulatory Care Challenges

1. How to oversee and address quality monitoring
2. How to pay for the necessary commitment to preventative health
3. How to pay for ongoing virtual services
4. Training a new set of executives and managers in this environment
5. How to get the regulatory environment to embrace expanded ambulatory care
6. How to navigate between patient and doctor preference as to site of care
7. How can hospitals and hospital systems adjust to the financial shifts inherent as more care moves towards the ambulatory environment

Thank you!

Arthur Klein, MD, BSMD

Previous President and Previous President Emeritus of the Mount Sinai Health Network  
Clinical Professor of Pediatrics and Administration at the New York Institute of  
Technology

Adjunct Professor, Mailman School of Public Health, Columbia University





# EL MODELO MADRID FRENTE AL COVID-19

**Enrique Ruiz Escudero**  
Consejero de Sanidad



**Comunidad  
de Madrid**

**SOMOS**

06/10/2022

# THE MADRID MODEL AGAINST COVID-19

**Mr. Enrique Ruiz Escudero**  
Cabinet Minister of Health



**Comunidad  
de Madrid**

**SOMOS**


06/10/2022



**MARZO 2020: LA OMS DECLARA AL COVID-19 COMO PANDEMIA EN ESPAÑA SE DECRETA EL ESTADO DE ALARMA**



CONSEJERÍA DE SANIDAD




**somos**

**MARCH 2020: WHO DECLARES COVID-19 A PANDEMIC SPAIN DECREES STATE OF EMERGENCY**



CONSEJERÍA DE SANIDAD



**somos**



## CÓMO HA AFECTADO ESTA PANDEMIA AL MUNDO



CONSEJERÍA DE SANIDAD

**615** millones de casos positivos  
**6,5** millones de fallecidos  
**255** millones de empleos perdidos  
**246** millones de casos de depresión grave  
*(la nueva ola silenciosa)*

**SOMOS**

## HOW THIS PANDEMIC HAS AFFECTED THE WORLD



CONSEJERÍA DE SANIDAD

**615** million positive cases  
**6,5** million deaths  
**255** million jobs lost  
**246** million cases of severe depression  
*(the new silent wave)*

**SOMOS**




## CÓMO HA AFECTADO ESTA PANDEMIA A LA COMUNIDAD DE MADRID



1,8 M  
casos



167.000  
hospitalizados



2,2M  
seguimientos  
domiciliarios

16.600  
UCI

28.000  
fallecidos



## HOW THIS PANDEMIC HAS IMPACTED THE COMMUNITY OF MADRID



1,8 M  
Cases



167,000  
Hospitalizations




2.2M  
At-home  
medical  
treatments

16,600  
ICU

28,000  
Deaths





¿CÓMO NOS HEMOS ENFRENTADO AL  
COVID-19 EN LA COMUNIDAD DE  
MADRID?



HOW THE COMMUNITY OF MADRID  
FACED COVID-19



CRITERIOS  
TÉCNICOS/ ZBS



PLANES DE  
ELASTICIDAD /  
CORREDOR DE UCI

TEST DE ANTÍGENOS /  
COMPRA MATERIAL



MANDO ÚNICO  
Sanidad pública y privada

VACUNACIÓN



HOSPITAL ZENDAL  
Hospital de IFEMA

## MODELO MADRID FRENTE AL COVID

En definitiva, diseñamos un 'Modelo Madrid frente al Covid-19', que conjugó salud y economía, permitiendo a la sociedad avanzar a pesar de la pandemia.

TECHNICAL  
CRITERIA/ ZBS



FLEXIBILITY PLANS/  
ICU NETWORK  
AGREEMENT

ANTIGEN TESTS/  
MATERIAL PURCHASES



SINGLE CONTROL  
Public and Private Health

VACCINATION



ZENDAL HOSPITAL  
IFEMA Hospital

## MADRID MODEL AGAINST COVID

In short, we designed a 'Madrid Model Against COVID-19', which combined health and economy, allowing society to move forward despite the pandemic.



**HOSPITAL DE IFEMA**  
**EN MENOS 24H**  
**4.000 PACIENTES ATENDIDOS**  
**1.250 PROFESIONALES**  
**1.200 CAMAS**

**IFEMA HOSPITAL**  
**IN LESS THAN 24 HOURS**  
**4,000 TREATED PATIENTS**  
**1,250 PROFESSIONALS**  
**1,200 BEDS**



## HOSPITAL ENFERMERA ISABEL ZENDAL



REFERENTE  
INTERNACIONAL



MAYOR UNIDAD  
REHABILITACIÓN  
FUNCIONAL

10.000  
PACIENTES  
ATENDIDOS

2,2 MILLONES  
VACUNAS  
ADMINISTRADAS

**somos**

## ENFERMERA ISABEL ZENDAL HOSPITAL



INTERNATIONAL  
BENCHMARK



LARGEST  
FUNCTIONAL  
REHABILITATION  
UNIT

10,000  
TREATED  
PATIENTS

2.2 MILLION  
VACCINES  
ADMINISTERED

**somos**





Comunidad de Madrid  
CONSEJERÍA DE SANIDAD

En otoño de 2020 comenzamos a perfilar el **PLAN OPERATIVO DE VACUNACIÓN FRENTE AL COVID-19**

El programa de vacunación poblacional **más ambicioso** de las últimas décadas: **Vacunar y vacunar** a la mayoría de la población en el **menor tiempo posible**

Comunidad de Madrid  
CONSEJERÍA DE SANIDAD

In the fall of 2020 we began to outline the **COVID-19 VACCINATION OPERATIONAL PLAN**

The **most ambitious** population vaccination program in recent decades: **Vaccinate and vaccinate** the majority of the population in the **shortest amount of time**




Comunidad de Madrid

CONSEJERÍA DE SANIDAD



LA VACUNACIÓN ES LA MEJOR ALTERNATIVA AL CONTROL DE LA PANDEMIA PORQUE PREVIENE LA TRANSMISIÓN DE LA ENFERMEDAD Y EVITA SUS CONSECUENCIAS MÁS GRAVES”



14,2 millones de vacunas administradas


93,6% población pauta completa

59,7% con dosis de recuerdo

Segunda dosis de refuerzo



VACCINATION IS THE BEST ALTERNATIVE TO PANDEMIC CONTROL BECAUSE IT PREVENTS THE TRANSMISSION OF THE DISEASE AND PREVENTS ITS MOST SERIOUS CONSEQUENCES”



14.2 million vaccines administered

93.6% population fully vaccinated

59.7% with booster doses

Second booster dose



Comunidad de Madrid

CONSEJERÍA DE SANIDAD



## VACUNADOS CON PAUTA COMPLETA EN EL MUNDO

Comunidad de Madrid  
CONSEJERÍA DE SANIDAD



85,4%



85,6%



86,3%



86,1%



81,8%



81,3%



78,2%



80,4%



75,7%



76,2%



67,7%



32,2%

## FULLY VACCINATED IN THE WORLD

Comunidad de Madrid  
CONSEJERÍA DE SANIDAD



85.4%



85.6%



86.3%



86.1%



81.8%



81.3%



78.2%



80.4%



75.7%



76.2%



67.7%



32.2%



## SITUACIÓN ACTUAL DE LA PANDEMIA



*María y Nicanor fueron los primeros en vacunarse contra el Covid19 en diciembre de 2020. Y los primeros en recibir la segunda dosis de refuerzo.*

### ACTUAMOS A 3 NIVELES:

#### 1. VACUNACIÓN

Desde el 26 de septiembre

- Vacunamos a 70.000 residentes en 700 centros
- A 90.000 trabajadores sociosanitarios
- Población menor 60 años inmunodeprimida


#### 2. MONITORIZACIÓN DIARIA

- Red Médicos Centinela Covid-19

#### 3. PROTECCIÓN A VULNERABLES

- Revisión de medidas: mascarillas transporte público

## CURRENT SITUATION OF THE PANDEMIC



*María and Nicanor were the first to get vaccinated against COVID-19 in December of 2020. They were also the first to receive the second booster dose.*

### WE RESPONDED ON 3 LEVELS:

#### 1. VACCINATION

Since September 26

- Vaccinated 70,000 residents in 700 centers
- 90,000 social and health workers
- Immunocompromised population under 60 years of age

#### 2. DAILY MONITORING

- Centinela COVID-19 Doctor Network

#### 3. PROTECTING THE MOST VULNERABLE

- Review of measures: public transport face masks




## ¿QUÉ HEMOS APRENDIDO DEL COVID-19?



**somos**

## WHAT HAVE WE LEARNED FROM COVID-19?



**somos**



**GRACIAS**



**Comunidad  
de Madrid**

**THANK YOU**



**Comunidad  
de Madrid**



# Current Status of Illicit Drugs; Consequences in Global Public Health; Covid and Associated Health Implications

**Dr. Bernard Fialkoff DDS**

**Periodontal/Implant/Laser Surgeon**

**President Foundation for a Drug Free World Americas Chapter**

**New York State Dental Society Chemical Dependency Committee**

**Pierre Fauchard Honoree**

**Fellow of the International College of Dentists**

**October 6, 2022**

## Purpose and Objectives

### PURPOSE

*Scientific findings and guidelines as regards Marijuana, CBD, Opioids in global health care. The importance of education based on science in the health and well being of the patient and its influence on public health.*

### OBJECTIVES

- Understand how education of the patient enables a model of value-based care by reducing drug addiction and misuse amongst patients and hence the community
- Recognize strategies for applying evidence-based medicine on illicit drug misuse and systemic repercussions as regards communities impacted by the physical and mental stress of the COVID-19 pandemic
- Understand how patient education based on scientific studies, such as from NIH, enable learned best practices to identify and address health equity in the community by reducing co-morbidity on Covid and other disease states
- Adopt pragmatic, professional education tools utilizing scientific findings to address the wellness needs of patient populations and communities at large.

### FINANCIAL DISCLOSURE

*No Financial Interests*



# *SOMOS Spain Symposium*

**Dr. Bernard Fialkoff DDS**  
**Practice Limited to Periodontics,**  
**Dental Implants Laser Periodontics**  
**Baysidedentist.com**  
**BernardFialkoffdds.com**  
**718 229 3838**

**New York State**  
**Dental Association**  
**Chemical Dependency Committee**




**New York State**  
**Dental Association**  
Chemical Dependency Committee



# **The Truth About Vaping, CBD, Medical and Recreational Marijuana, Opioids**

**Dr. Bernard Fialkoff DDS**  
**Practice Limited to Periodontics,**  
**Implantology,**  
**Laser, 3D Scan Imaging, Sinus Grafting**  
**BernardFialkoffDDS.com**  
**BaysideDentist.com**







New York State  
Dental Association  
Chemical Dependency Committee



**With 107, 622 illicit drug deaths  
in 2021...Up 15 % over 2020.  
CDC**

**What is the role of the health practitioner in this  
global drug crisis ?**



Into whatsoever houses I enter, I will enter to  
help the sick, and I will abstain from all  
intentional wrong-doing and harm, especially  
from abusing the bodies of man or woman....

Practice two things in your dealings with  
disease: either help or do not harm the  
patient.



- Cigarette smoking causes more than 480,000 US deaths each year.
- US COVID-19 deaths, about 385,000 in 2020, more than 386,000 in 2021. *CDC*
- Overall, mortality among both male and female smokers in the United States is about 3X higher than that amongst non-smokers. *CDC*
- Electronic cigarettes rose as a supposed non-toxic alternative to tobacco smoking. Vapes and e-cigs morphed into complex rigs with diverse ingredients / flavors delivering a strong nicotine exposure.
- From 2018 to 2019, teens using electronic cigarettes increased by 80%.



New York State  
Dental Association  
Chemical Dependency Committee



Vaping utilizes Propylene Glycol to carry the nicotine and flavorings; which break down into acetic acid, lactic acid, and propionaldehyde; All toxic to enamel and soft tissues. In addition, the water molecules in saliva and oral tissue can bond to the molecules of the propylene glycol, leading to long term xerostomia.



Vegetable Glycerin another common e-juice carrier increases microbial adhesion to enamel by four times - causing 27% decrease in enamel hardness. The sticky, viscous vegetable glycerine enables plaque adhesion, causing caries on the softer teeth; And periodontal edema, recession, inflammation.....



E-cigarette aerosol  
Flavorings - Diacetyl, a chemical linked to a  
serious lung disease

**Cinnamon flavors** - Cinnamaldehyde,  
**Cherry flavors** - Benzaldehyde



Heavy metals ( Nickel, tin, and lead)

Cancer-causing chemicals

Nicotine

## Popcorn Lung

Blockbuster Video Popcorn Butter Flavor



- This irreversible respiratory disease was named after the factory workers inhaled artificial butter flavor while working, causing the small airways in the lungs become irreversibly scarred and constricted, impairing breathing.
- Diacetyl and a closely related compound, 2,3-pentanedione, cause popcorn lung ( constrictive bronchiolitis obliterans)
- Diacetyl has been found in many e-liquids with sweet flavors.



## THE TRUTH ABOUT VAPING




Young people who use e-cigarettes may be more likely to smoke cigarettes in the future.

Nicotine harms developing adolescent brain which forms until about age 25. ; affecting control of attention, learning, mood, and impulse control. By binding to pleasure receptors in the brain a release of dopamine occurs ( temporary euphoria ). The brain receptors adapt producing less dopamine and hence the user now addicted, craves nicotine just to feel normal.

The CDC found that 99% of the e-cigarettes contain nicotine. Some vape product labels do not disclose that they contain nicotine, and some vape liquids marketed as containing 0% nicotine have been found to contain nicotine.

Nicotine –

- Apnea and lung damage, in addition to the chemicals and toxins in ecigs
- Acid reflux
- Tachycardia activating the “fight or flight response”
- Insulin resistance, affecting diabetics
- Negative reproductive organ effect.



## Vaping Conclusions



- Ecig / vapes' e-juice aerosol leave chemical lung residues.
- Aldehydes and other components found in vaping liquids can impair the immune function of cells found in the airway and lungs.
- As with cigarette smoking, vaping compromises the respiratory immune defense system making one more susceptible to lung infections. ( Covid )

The e-cigs/vapes' nicotine, effect the cardiovascular system. causing impaired flow-mediated dilation cardiovascular diseases

- Ear, Eye and Throat Irritation is common among e-cig/vape users.
- Youth addiction to nicotine, early adolescence changes to the brain ; tendency to life-long addiction affecting our future leaders.
- E Cig Vasoconstriction reduces ability to fight off Red Complex Bacteria and periodontium receives less oxygenation / nutrients. Gram neg *terponema denticola*, *porphyromonas gingivalis*, and *tannerella forsythia*, thrive in a de-oxygenated environment causing gingivitis and periodontitis.
- Vaping nicotine and heat from the vapor increases the risk of gum recession and exposes root cementum increasing thermal sensitivity.



# Marijuana and the Opioid Epidemic



Lets look at more puzzle pieces.....

Smoking, Alcohol, Vaping, Flavors, Nicotine.....

Medical and Recreational Marijuana, CBD, Opioids

**THC and CBD are in both marijuana and hemp.**

**Marijuana contains much more THC than hemp.**

**Hemp contains much more CBD.**

**Hemp is primarily used to describe nonintoxicating strains of cannabis that are harvested for industrial uses and cannabidiol (CBD) extraction. Industrial hemp is used for the production of items such as paper, textiles, biodegradable plastics, and fuel.**



## CBD

- Touted for pain relief, sleep disorders, anxiety.
- Replacing opioids or to treat addiction.
- Claims on reduction of inflammation and muscle spasm and hence relief of TMJ/TMD, Tooth Sensitivity.
- Purported antibacterial properties - Prevent caries, tooth pain and periodontitis
- Arthritis, chrone's, diabetes, MS,

This is stated to occur via CBD interaction with the CB2 receptors in the brain, which mediate the immune functions of the body.

---

There is little scientific evidence on CBD to substantiate the claims.

Concern of no consistent oversight, on the reliability, purity, safety and dosage of nonprescription CBD products.

A recent CBD products online study revealed more than ¼ contained different levels of CBD than labelled ! In addition, THC was found in 18 products .

Mayo Clinic 2021

- Dosed medications - Many drugs are broken down by enzymes in the liver, and CBD may compete for or interfere with these enzymes, leading to over and under dosing, called altered concentration. The altered concentration may lead to the medication not working, or an increased risk of side effects.
- CBD affects other medications body concentrations / potency by competing or interfering with liver enzymes; May need liver function tests.
- Can cause liver problems, by using it with other medications that can also affect the liver; such as acetaminophen.
- Can increase the risk of bleeding with anticoagulants like ibuprofen and warfarin.
- Can increase the potency of sedatives, creating severe health risks.
- Because of these potential risks, it is vital that any use of CBD or medical marijuana is included in the medical history and to consult with the physician.



**The FDA stance is that there are many unanswered questions about CBD products outside the approved drug context of 0.3 % THC in the CBD.**

**For example, there are open questions such as:**

- **How much CBD is safe to consume in a day?**
- **How does it vary depending on what form it's taken?**
- **Are there drug interactions that need to be monitored?**
- **What are the impacts to special populations, like children, the elderly, and pregnant or lactating women?**
- **What are the risks of long-term exposure?**

**These and other questions need to be answered via scientific studies and data evaluation.**

**The FDA has approved CBD only for the following medical utilization -**

- 1. Cannabidiol (Epidiolex) for epilepsy**
- 2. Dronabinol (Marinol, Syndros) for nausea / vomiting caused by cancer chemotherapy and for anorexia associated with weight loss in people with AIDS.**

**It has not been approved for any dental use.**

**CBD cannot be legally marketed as an inactive ingredient in OTC drug products that are not reviewed and approved by the FDA. Mar 22, 2021.**



### Endocannabinoid System

CB1 receptors are primarily active in your brain and central nervous system, where they interact with neurons.

CB2 receptors, on the other hand, are mostly found on immune cells and gi system.

THC is a CB1 and CB2 agonist .  
THC binds with receptors -- mostly in the brain -  
Euphoria.

CBD generally acts as a CB1 and CB2 antagonist.  
Doesn't cause euphoria. Instead, influencing  
receptors outside of the CNS – Anti-inflammatory.



Medical marijuana ( Varying Levels of CBD and THC ) may have possible therapeutic effects.

Depending on the state, it may be utilized, within certain requirements and qualifying conditions, such as :

- Alzheimer's disease
- Amyotrophic lateral sclerosis (ALS)
- HIV/AIDS
- Crohn's disease
- Epilepsy and seizures
- Glaucoma
- Multiple sclerosis and muscle spasms
- Severe and chronic pain
- Severe nausea or vomiting caused by cancer treatment

• No Dental Application





**Over 90 % of medical marijuana in US contains high levels of THC.**

**Majority of medical marijuana dispensed had THC levels of up to 15 % - causing mind altering effects.**

**This is problematic because 60-80 % of patients who use medical marijuana use it for pain relief.**

**The higher the concentration of THC, the greater risk for developing dependency and tolerance more quickly.....requiring higher and higher concentrations needed to get the same level of pain relief. Common tolerance problem with all drugs.**



**Did You Know?**

A good vaporizer will deliver more THC per gram of cannabis than smoking because no combustion takes place.

A Dab Rig device uses very hot ( 100's \* F ) metal, ceramic, glass, or quartz to instantly vaporize concentrated herbal or plant extracts within a glass chamber. Then the Dab is added, the vapor fills the chamber and the user takes a hit.

Names - E-cigs, hookahs, mods, vape pens, vapes, dab rigs.




Vape Pens in past few years, largely replaced joints and blunts due to their stealth factor, ease of use, and potency. The THC % of resin usually hovers somewhere around 45 or 50 percent, while THC distillate % ranges from 85 or 90 % THC, causing psychotic effects ! Harm magnified in high THC levels



THC extracted into an oil can be evaporated into a sticky goo or wax that is smoked or, more popularly, vaporised. That goo can be further refined into a hard glass-like substance often called "shatter."

#### Dabbing

This concentrated form of marijuana is heated quickly on a very hot surface, vaporised, and then inhaled through a special apparatus, sometimes called a "dab rig" or an "oil rig." This process is called dabbing.



The THC content in dabs ranges from 60% to as high as 90%.7



## Healthy Kids Colorado Survey August 2020

- **32.4%** of youth **drove a vehicle after using marijuana** in the past month, **up from 9.0%** in 2017
- **More than half** of high school students who use marijuana reported that they **dab marijuana** to get high
- Dabbing" is a method of inhaling **highly concentrated THC** (commonly referred to as hash oil, wax or shatter) using a **blow torch-heated** delivery system commonly referred to as a dab rig

**DEA - In order to meet the definition of 'hemp,' and**

**thus qualify for the exemption from schedule I, the derivative must not exceed the 0.3% D9-THC limit.**

**Marijuana from the plant Cannabis sativa and every compound, manufacture or preparation of such plant, are Schedule I controlled substances.**

**Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Examples are: heroin, (LSD), marijuana, ecstasy, methaqualone and peyote.**

**Unless they meet the definition of hemp limit -**

**0.3% D9-THC DEA 21 U.S.C. 802(16) – then they are schedule 1 and illegal at federal level.**




New York State  
Dental Association  
Chemical Dependency Committee

**Marijuana use has been shown to increase risk of opioid misuse.**

**Marijuana use linked to social anxiety, depression, suicide and schizophrenia.**

**3 of 10 marijuana users become addicted to marijuana use, with increased risk correlated to early onset of use as youth.**

**CDC**



## NEW ENGLAND JOURNAL OF MEDICINE

Table 1. Substance Use and Sexual Behavior among Colorado High-School Students, According to Use or Nonuse of Electronic Vapor Products, in 2017.<sup>a</sup>

Variable	Recent Use of Electronic Vapor Product <sup>†</sup>	
	No (N=31,991)	Yes (N=13,394)
	<i>(95 percent confidence interval)</i>	
Binge drinking on ≥1 day in past 30 days‡	6.1 (5.6–6.5)	43.0 (41.3–44.7)
Use of opioid pain medicine without a prescription in lifetime	7.1 (6.7–7.5)	26.0 (24.8–27.2)
Use of marijuana in past 30 days	7.6 (6.7–8.4)	50.1 (49.2–52.7)
Use of cocaine >1 time in lifetime	1.4 (1.1–1.6)	14.2 (13.2–15.2)
Sex with ≥1 partner during past 3 mo	14.6 (13.7–15.5)	45.1 (43.8–46.4)
Use of heroin >1 time in lifetime	0.5 (0.3–0.6)	3.7 (3.2–4.1)
Use of methamphetamines >1 time in lifetime	0.6 (0.5–0.8)	5.0 (4.5–5.6)



## **Research from the 2021 ADA Council confirms the increased use of marijuana among dental patients and the growing need for more clinical guidance**

CBD, Medical Marijuana and Recreational Marijuana products do not carry the American Dental Association (ADA) seal of approval

**“ The oral health effects associated with smoking cannabis that include periodontal complications, xerostomia and leukoplakia are a concern to dentists,” said Dr. Ana Mascarenhas, B.D.S., Chair of the ADA Council on Scientific Affairs.....,**

**The development of best practices for the management of those under the influence of cannabis is in the best interest of our profession.”**

## **Comorbidity / Therapeutic Considerations**



**As Health Practitioners we know the ECS as one of the most important physiologic systems involved in HOMEOSTASIS utilizing and producing endocannabinoids to respond to stress, illness, and injury.**

**Scientific evidence exists that patient’s endocannabinoid system (ECS) may not be functioning optimally.**

**Certain foods and activities can help the ECS function optimally, improve your health, and enhance the effectiveness of medical treatment.**

**Essential fatty acids, eggs, chocolate, herbs, spices, walnuts, flax seeds, a healthy ratio of omega-3 and omega-6 fatty acids, echinacea, turmeric, tea.**

**Exercise, stress reduction ( social interaction, unstructured play and positive activities, spiritual pursuit, massage ) can naturally stimulate and enhance the activity of the ECS**

**Pesticides, stress, alcohol, negative lifestyle and poor diet impair the ECS**



## Cannabis Results

Whether oral cannabinoids reduce the intensity of chronic cancer pain is not completely clear. Recent long-term studies are not encouraging.

Literature data shows that oral cannabinoids have inadequate efficacy in rheumatological pain conditions.

Oral cannabinoids do not reduce acute postoperative or chronic abdominal pain.

Long-term safety assessment of medicinal cannabis is based on scant clinical trials and the safety interpretation should be taken cautiously.

More research is needed to evaluate the adverse effects of long-term use of medical cannabis.

### **Cannabinoids and Pain: New Insights From Old Molecules**

Front. Pharmacol., 13 November 2018 | <https://doi.org/10.3389/fphar.2018.01259>

## Evidence

- 2020, December; J. Clinical Anesthesia
- Increased **anesthesia requirements** for marijuana users undergoing surgery for tibial fracture
- Marijuana users had **higher pain scores** in recovery
- Marijuana users received **58% more opioids per day** while in the hospital

### **The association between preoperative cannabis use and intraoperative inhaled anesthetic consumption: A retrospective study**

[Ian C Holmen](#)<sup>1</sup>, [Jeffrey P Beach](#)<sup>2</sup>, [Alex M Kaizer](#)<sup>3</sup>, [Ramakrishna Gumidyal](#)  
[Jclinanesthesiology Jul 9, 2020.109980.](#)



## Evidence

- 2019, J Pain, September, Boehkne; **High frequency medical cannabis** use is associated with **worse pain** among individuals with chronic pain
- 2019, CMAJ Open, December; Cannabis use is **not** associated with **reduced opioid use** or longer treatment retention when used during methadone maintenance therapy in patients with **opioid use disorder**.



- 2020, PLOS One, March, Cash; THC concentrations in dispensaries in regulated markets have concentrations are often twice or even three times **too high** for pain relief and may lead to other negative psychiatric risks (**THC 15-20% average**)

“ Its not working...I need something stronger “ !

**Local anesthesia with epinephrine may exacerbate cannabis-related tachycardia and hypertension.**

**These cardiovascular effects require a higher oxygen demand by the heart and body, and thus may contribute to diminished O<sub>2</sub> blood saturation levels.**

**The effect of cannabis on the cardiac muscles thus can potentially lead to cardiac ischemia.**

**The overall respiratory symptoms of cannabis are further complicated by anxiety and carbon monoxide absorbed during the act of smoking.**

**Employ caution when using local anesthesia with epinephrine for a patient under the influence of cannabis.**



## General Anesthesia

**Cannabis potentiates cardiac arrhythmias and respiratory depression**

**It is recommended that the use of cannabis be ceased 72 hours prior to using general or regional anesthesia.**

**In addition, during general anesthesia or IV sedation, potentiation is possible and airway parameters must be monitored.**

**CNS depression in the presence of benzodiazepines, alcohol, antihistamines, and muscle relaxants is enhanced.**

**Strong evidence supports an increased risk for psychotic symptoms or panic attacks related to THC, along with drug dependence.**

## Surgical Considerations

**Cannabis users are advised to cease their habit of smoking before and after surgical procedures, Increase in alveolar osteitis (dry socket) and implant failures have been documented.**

**Healing time will be prolonged and that there is a risk of increased infection in smokers versus non-smokers.**

**Negative pressure created by the act of smoking can rupture a healing blood clot and pain.**

**As smoking reduces blood supply to the alveolar nerve, intensified pain may be experienced.**

**Substances that contaminate cannabis, such as nitrogenous and hydrocarbons, are noxious to healing sites and can lead to chronic infections of the bones, such as osteomyelitis.**

**Lowered oxygen levels increase bleeding time during surgical procedures and during recovery afterwards.**



## Dental Considerations

Chronic use of cannabis is associated with gingival inflammation, gingival hyperplasia, and alveolar bone loss, tripling risk of severe periodontitis.

Darling et al. reported that 70% of cannabis users described a transient sensation of xerostomia immediately following usage. Only 18.6% of cigarette-smoking control patients experienced similar symptoms.

Parasympatholytic properties of cannabis role and hyposalivation associated with the increased prevalence of periodontal disease.

Poor oral hygiene is more frequently seen in cannabis users compared to non-users, presenting with higher levels of decay and plaque, increased periodontal disease. "cannabis stomatitis".

When smoked, cannabis is deeply inhaled and the toxins damage alveolar cells in the lungs and cause the airway to be hyper-reactive. These components contribute to concerns related to oxygen deprivation and dyspnea with the use of epinephrine.

## Clinical and Ethical Considerations

Determining if the patient is under the influence of cannabis is very important when considering proper treatment and obtaining a valid consent. Cannabis intoxication can be difficult to determine as there are no THC accurate rapid tests without extensive laboratory examination.

When approaching patients who are suspected of being under the influence of cannabis, it is important to take note of behavioral changes such as euphoria, slowed cognition, impaired memory and coordination, and lack of focus.

A patient's altered state may pose ethical and clinical dilemmas when explaining treatment, management and completing consent forms for procedures.

Look for red eyes (vasodilation), decreased pupillary light reflex, smooth eye tracking, dry mouth, impaired short-term memory, impaired motor skills, euphoria or relaxation

Increased heart rate and blood pressure, breathing difficulty (relaxed bronchi)


History of chest pain, fatigue, cardiac arrest, drowsiness.





***“It is important to alert the public that using marijuana in the teen years brings health, social, and academic risk.”***

**Dr. Volkow Director, National Institute on Drug Abuse (NIDA)**



CDC

**New England J Med 6/2014**

**Research on Teens, an age group in which the brain rapidly develops, suggests that marijuana impairs critical thinking and memory functions during use and that these deficits persist for days after using.**

**In addition, a long-term study showed that regular marijuana use in the early teen years lowers IQ into adulthood, even if users stopped smoking marijuana as adults.**

September 23, 2020  
**Associations Between Prenatal Cannabis Exposure and Childhood Outcomes**

Sarah E. Paul, BA<sup>1</sup>; Alexander S. Hatoum, PhD<sup>2</sup>; Ebony B. Carter, MD<sup>3</sup>; Cynthia E. Rogers, MD<sup>2</sup>  
**JAMA Psychiatry. Published online September 23, 2020.**



**Women who used cannabis during pregnancy were more likely to have children with social problems, impulsivity and attention problems, and psychotic-like experiences that can be predictive of disorders like schizophrenia.**

**Prenatal cannabis exposure and its correlated factors are associated with greater risk for psychopathology during middle childhood. Cannabis use during pregnancy should be discouraged.**




Amer J of Psychiatry in Advance (doi: 10.1176/appi.ajp.2017.17040413)

Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States

Dr. Mark Olfson, M.D., M.P.H., et al

Conclusions: Cannabis use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.



Marijuana leads to Leads to Opioids  
This month in Psychopharmacology 2020

J Law Med Ethics. 2020 Jun; 48

Cannabis as a Gateway Drug for Opioid Use Disorder

A.R. Williams et al

Conclusions; Through a combination of genetic and environmental factors, it is highly likely that adolescent cannabis use can meaningfully increase risk of the initiation of opioid use and development of Opioid Use Disorder.

New York State  
Dental Association  
Chemical Dependency Committee

### Cannabis Use and Opioid Misuse in Adults September 2020

- 75,949 adults **aged ≥ 50** who participated in the year 2002–2014 (NSDUH)
- **3.8%** of the older adults reported past-year marijuana use (estimate **3.5 million** older adults Americans)
- **Past-year marijuana use** was very common (~30%) among **non-medical opioid dependence** respondents
- **Past-year marijuana use** was significantly associated with an increase in odds of reporting **opioid dependence**, and **past-year non-medical use opioids**

**Dr. Bernard Fialkoff DDS**  
**Practice Limited to Periodontics, Implantology,**  
**Laser, 3D Scan Imaging, Sinus Grafting**  
[BernardFialkoffDDS.com](http://BernardFialkoffDDS.com)  
[BaysideDentist.com](http://BaysideDentist.com)






### Cannabis use on the rise in most jurisdictions where non-medical use legalized

- 2020 World Drug Report, United Nations Office on Drugs and Crime
- Canada, Uruguay and 11 jurisdictions in the United States allow the manufacture and sale of cannabis products for **non-medical use**
- In Colorado and Washington, two of the first states to pass legalization, **increases in non-medical use of cannabis** among adults, past month and daily, or near daily use has **outstripped the national average** since 2012
- Increases have also been seen in Uruguay (since 2011) and Canada (since 2016), coinciding with legalization

<https://www.unodc.org/wdr2020/wdr2020-booklet-1.pdf>



## Global Drug Survey Results During Pandemic September 11, 2020


- N=55,000
- A considerable proportion of respondents **increased their use of cannabis** (44%), prescription benzodiazepines (34%) and prescription opioids (28%).
- Almost half (48%) survey respondents said they had increased the amount of **alcohol** they drank during the pandemic

[www.russellwebster.com/gds-covid-uk](http://www.russellwebster.com/gds-covid-uk)



## UNITED NATIONS WORLD DRUG CONFERENCE CONSENSUS 2016

### “ EDUCATION “




Education is Key to Empower Educated Patient Decision Making.






Education Based on Science  
To Improve Community Public Health



*Gracias Somos !*





New York State  
Dental Association   
Chemical Dependency Committee

*Thank you !*

*Dr. Bernard Fialkoff DDS  
Practice Limited to Periodontics,  
Dental Implants Laser Periodontics  
Baysidedentist.com  
BernardFialkoffdds.com  
718 229 3838*





## **Youth anxiety in the COVID era: An update on research and treatment to help kids, caregivers, & clinicians meet the challenges of these times**

**Sandra S. Pimentel, PhD**


Chief, Child & Adolescent Psychology  
Psychiatry and Behavioral Sciences Department  
6 October 2022

### **LEARNING OBJECTIVES**

- Review the most current research on youth anxiety and COVID-era youth mental health challenges
- Consider a developmental framework and novel approaches for targeting pandemic-related disruptions in screening, assessment, and treatment
- Identify and incorporate specific strategies to incorporate into CBT for anxious youth to address these challenges

**NO FINANCIAL DISCLOSURES**

**Montefiore**



## Development as a path

[www.cdc.gov/ActEarly](http://www.cdc.gov/ActEarly)

Montefiore

## Fears across development

- **Infants**
  - Loud noises, startle response, strangers
- **Toddlers/Pre-School**
  - Imaginary creatures, boogey man, separation, dark, animals
- **School-age**
  - Injury, safety, natural events (thunderstorms), death
- **Pre-Adolescent and Adolescence**
  - Health, academic performance, social competence

Montefiore





## Why anxiety in youth?

- EVEN PRE-PANDEMIC - Anxiety most common class of psychiatric illness in youth!
- Functional impairments
- Anxiety & MDD in the Top 10 list of YLD (Global Burden of Disease)
- Preceding drug and alcohol dependence by 10 years
  - Follow up study in children who received CBT for anxiety: Maintained gains in anxiety & reduced risk of substance abuse more than 7 years later (Kendall et al., 2004)
- Premature mortality
  - Chronic medical illnesses; Suicide
- Onsets in childhood, adolescence, and young adulthood
  - 75% of lifetime psychiatric illnesses emerge < 24 years (USA; Kessler et al., 2005)

Montefiore



European Neuropsychopharmacology



Volume 27, Issue 6, June 2017, Pages 543-553



ANNA-MONIKA FOUNDATION

### Mechanisms underlying the early risk to develop anxiety and depression: A translational approach

Ned H. Kalin<sup>1</sup>\*



Montefiore



# Youth Anxiety: Functional Impairments

- Social
  - Peer relation problems; making friends; likeability; social competence
- Educational/Occupational
  - Some aspects of performance; achievement level; work adjustment in later adulthood
- Family Functioning
  - Accommodation, family distress, ability to cope independently; relationship quality



Letter to the Editor

## Fear and Missing Out: Youth Anxiety and Functional Outcomes

Anna C. Sharp, Ph.D., Philip C. Kendall, Ph.D.

First published: 24 October 2016 | <https://doi.org/10.1111/cpsp.12199> | Citations: 38

Montefiore

Child Psychiatry Hum Dev. Author manuscript; available in PMC 2015 Aug 1  
 Published in final edited form as:  
 Child Psychiatry Hum Dev. 2014 Aug; 45(4): 388-407.  
 doi: 10.1007/s10578-013-0410-x

PMCID: PMC3689467  
 NIDMSID: NIDMS532136  
 PMID: 24126543

### Somatic Complaints in Anxious Youth

Sarah A. Crawley, Ph.D.,<sup>1,2</sup> Nicole E. Caporino, Ph.D.,<sup>2</sup> Boris Birmaher, M.D.,<sup>3</sup> Giulio G. Ginsburg, Ph.D.,<sup>4</sup> John Flament, Ph.D.,<sup>5</sup> Anne Marie Albano, Ph.D.,<sup>6</sup> Joel Sherrill, Ph.D.,<sup>7</sup> Dana S. Kobak, M.D., Ph.D.,<sup>8</sup> Scott M. Compton, Ph.D.,<sup>9</sup> Mona Ryan, M.D.,<sup>10</sup> James McCracken, M.D.,<sup>9</sup> Elizabeth G. Escabi, Ph.D.,<sup>9</sup> Courtney Kenyon, Ph.D.,<sup>8</sup> John March, M.D., M.P.H.,<sup>8</sup> John T. Walkup, M.D.,<sup>10</sup> and Philip C. Kendall, Ph.D.<sup>2</sup>

– Author information • Copyright and License information • Disclaimer

Table 1  
 Frequency of Physical Symptoms by Principal Diagnosis at Presentation

Presentation Symptom	N (%)			
	SAD (n = 80)	SPD (n = 75)	GAD (n = 23)	N
<b>Head disturbance</b>				
Tension/aching	10.0%	12.0%	43.0%	
Headache or uncomfortable eye contact	17.5	17.1	17.3	
Feeling dizzy or too close	20.4	15.8	19.4	
Supercorn	12.5	22.7	4.4	
Lighting or not seeing clearly	4.2	13.8	30.4	
<b>Open respiratory</b>				
Rhinitis/sinusitis	50.0	40.9	22.8	
Allergies	4.2	17.3	42.8	
Nose bleed	11.7	13.9	49.1	
Dry mouth	4.2	12.1	13.2	
Coughing or wheezing	19.9	13.1	11.3	
Flu	6.9	12.1	13.2	
<b>Eye</b>				
Itchy/red	11.7%	11.3%	14.6%	
Itchy/red/pain in white	10.8	10.8	12.2	
Itchy/red/pain in conjunctiva	17.8	17.8	16.1	
Swelling	12.7	12.9	12.2	
<b>Respiratory</b>				
Coughing or wheezing/flu	19.9	22.1	18.2	
Shortness of breath	12.7	17.0	12.1	
Hoarseness/voice	4.2	17.1	12.1	
Trouble swallowing or choking	12.7	17.3	14.1	
Intermittent wheezing	4.2	10.4	14.1	
Difficulty breathing	4.2	7.5	12.2	
Wheezing after exercise	12.7	10.8	14.1	
Wheezing or coughing in winter or fall	12.2	7.5	14.1	

Table 2  
 Presentation Symptom

Presentation Symptom	N (%)		
	SAD (n = 80)	SPD (n = 75)	GAD (n = 23)
<b>Can't lose weight</b>	0.0%	0.0%	0.0%
<b>Elimination/gastro</b>			
Nausea/vomiting	23.8	16.0	12.2
Feeling bloated or gassy	0.0	16.3	17.2
Constipation	0.0	2.7	9.1
Frequent urination	0.0	3.0	9.1
Diarrhea	4.2	7.8	17.2
Heartburn	0.0	3.0	6.1
Pain with urination	0.0	7.4	7.0
<b>Head</b>			
Dry skin	13.5	22.9	13.1
Acne	18.8	17.7	27.9
Shed hair	0.0	7.7	4.3
Hives	4.2	2.7	3.0
<b>Other</b>			
Feeling flushed or warm	18.8%	17.0%	12.2%
Feeling cold or chilled	12.8	22.7	18.2
Agitation/irritability	18.8	17.9	25.8
Waking up often	0.0	13.9	24.2
Racing heartbeat	4.2	7.8	18.2
Cold or chills/fever	18.8	9.1	0.0
Dizziness/vertigo	0.0	3.0	9.1
Heat loss or bottle loss	0.0	7.8	3.0
Swallowing, water retention	0.0	4.1	3.0



# Emerging Adulthood & Developmental milestones

**LEAF**

Name: \_\_\_\_\_ Date: \_\_\_\_\_

Rate how independent your/our child is on these tasks:

W None of the Time 25% of the Time 50% of the Time 75% of the Time 100% of the Time

1. Task set/Task

- 1.1 Follow and/or understand (and) without prompting
- 1.2 Use skills to make and follow simple rules created
- 1.3 Make and understand simple rules used to plan/coordinate
- 1.4 Prepare and use simple tasks (e.g.,
- 1.5 Follow a sequence of benefits, individual plan
- 1.6 Use one benefit
- 1.7 Establish routine
- 1.8 Establish expectations of performance and goals
- 1.9 Keep control on benefits and/or adjustments
- 1.10 Present control and to create

2. Adaptive Task

- 2.1 Support needs/complexity (2 separate rows each)
- 2.2 Manage any personal or social
- 2.3 Use control of and plan on spending and saving
- 2.4 Do any social skills on face
- 2.5 Do any social skills on face

3. Adaptive Behavior


- 3.1 Establish and/or follow
- 3.2 Establish and/or follow
- 3.3 Establish and/or follow
- 3.4 Establish and/or follow
- 3.5 Establish and/or follow
- 3.6 Establish and/or follow
- 3.7 Establish and/or follow
- 3.8 Establish and/or follow
- 3.9 Establish and/or follow
- 3.10 Establish and/or follow

4. Adaptive Behavior

- 4.1 Establish and/or follow
- 4.2 Establish and/or follow
- 4.3 Establish and/or follow
- 4.4 Establish and/or follow
- 4.5 Establish and/or follow
- 4.6 Establish and/or follow
- 4.7 Establish and/or follow
- 4.8 Establish and/or follow
- 4.9 Establish and/or follow
- 4.10 Establish and/or follow

Albano, AM & colleagues (2018)

Montefiore



MAPS & TRENDS  
**DISPARITY EXPLORER**

### The COVID Racial Data Tracker

Racial Data Dashboard About Complete Dataset Help Us Get Better Race and Ethnicity Data

**COVID-19 is affecting Black, Indigenous, Latinx, and other people of color the most.**



*80% correlation between primary caregiver stress levels and that of their children.*

Montefiore

## Food & financial insecurity



Children aged 5 to 16 years with a probable mental disorder were more than twice as likely to live in a household that had fallen behind with payments (16.3%), than children unlikely to have a mental disorder (6.4%)

e



# Lockdown made life worse for two in five children, NHS report says

By Philippa Roxby  
Health reporter

22 hours ago

Coronavirus pandemic



Mental Health of Children and Young People in England, 2020: Wave 1 follow up to the 2017 survey

PDF hosted at [www.nhs.uk](https://www.nhs.uk) | Last revised: Available online at: <https://www.nhs.uk>

Survey

Publication Date: 22 Oct 2020  
Geographic Coverage: England  
Geographical Granularity: Region, County  
Data Range: 1st Jul 2019 to 31st Aug 2020

“They said their biggest anxieties were about missing school and family and friends contracting Covid-19.”

Montefiore

TABLE 1. Respondent characteristics and prevalence of adverse mental health outcomes, increased substance use to cope with stress or emotions related to COVID-19 pandemic, and suicidal ideation — United States, June 24–30, 2020

Characteristic	All respondents who completed surveys during June 24–30, 2020 weighted* no. (%)	Conditions				Started or increased substance use to cope with pandemic-related stress or emotions <sup>3</sup>	Seriously considered suicide in past 30 days	≥1 adverse mental or behavioral health symptom
		Anxiety disorder <sup>1</sup>	Depressive disorder <sup>1</sup>	Anxiety or depressive disorder <sup>2</sup>	COVID-19-related TSUD <sup>1</sup>			
All respondents	3,470 (100)	23.5	24.3	30.9	26.3	13.3	10.7	40.9
Gender								
Female	2,784 (50.0)	20.3	23.9	31.5	24.7	12.2	8.9	41.4
Male	2,676 (48.9)	24.7	24.8	30.4	27.9	14.4	12.6	40.5
Other	10 (0.2)	20.0	30.0	30.0	30.0	10.0	0.0	30.0
Age group (yrs)								
18–24	731 (13.6)	49.1	52.3	62.9	48.0	24.7	25.5	66.2
25–44	1,911 (34.9)	35.3	32.5	40.4	36.0	19.5	16.0	51.5
45–64	1,695 (34.6)	16.1	14.4	20.1	17.2	7.7	3.8	23.1
≥65	933 (17.1)	8.2	5.8	8.1	9.2	3.0	2.0	15.1
Race/Ethnicity								
White, non-Hispanic	3,453 (63.1)	24.0	22.9	29.2	25.3	10.6	7.9	37.8
Black, non-Hispanic	663 (12.1)	23.4	24.6	30.2	30.4	18.4	15.1	44.2
Asian, non-Hispanic	256 (4.7)	14.1	14.2	18.0	22.1	6.7	6.8	31.9
Other race or multiple races, non-Hispanic <sup>4</sup>	164 (3.0)	27.8	29.3	33.2	28.3	11.0	9.8	43.8
Hispanic, any (total)	885 (16.2)	35.5	33.3	40.8	35.1	21.9	18.6	52.1
Unknown	50 (0.9)	38.0	34.0	44.0	34.0	18.0	26.0	48.0
2019 Household income (USD)								
<25,000	741 (13.6)	30.6	30.8	36.8	29.9	12.5	9.9	45.4
25,000–49,999	1,123 (20.5)	28.0	25.6	33.2	27.2	13.5	10.1	43.9
50,000–99,999	1,775 (32.5)	27.1	24.8	31.6	26.4	12.6	11.4	40.3
≥100,000	831 (15.4)	13.2	11.7	13.7	11.7	5.2	3.7	37.8
Missing	116	11.6	11.6	11.6	11.6	11.6	11.6	35.1
Missing	39	3.9	3.9	3.9	3.9	3.9	3.9	41.5



CDC Center for Disease Control and Prevention

Morbidity and Mortality Weekly Report (MMWR)

### Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020

Weekly Report 14, 2020 (49(24))

Maria E. Cougle, PhD; Richard L. Cook, MD; Emily E. Franks, PhD; Jennifer L. Hays, PhD; Joseph P. Miller, PhD; Christopher M. Moore, PhD; David S. Reardon, PhD; Matthew J. Ross, PhD; Pauline A. Robinson, PhD; Lisa K. Alexander, PhD; Lisa A. Sargent, PhD; Charles A. Coble, MD, PhD; Mark E. Hyatt, MD, PhD; Joseph F. Murray, PhD; Joseph B. Applegate, MD

Montefiore



JAMA Pediatrics Search All Enter Search Term

New Online Views 37,699 Citations 1 Altmetric 1757

Download PDF More CME & MOC Cite This Permissions

Original Investigation ONLINE FIRST FREE

August 9, 2021

# Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19

## A Meta-analysis

Nicole Racine, PhD, RPsych<sup>1,2</sup>; Brée Anne McArthur, PhD, RPsych<sup>1,2</sup>; Jessica E. Cooke, MSc<sup>1,2</sup>; et al

> Author Affiliations | Article Information


JAMA Pediatr. Published online August 9, 2021. doi:10.1001/jamapediatrics.2021.2482

COVID-19 Resource Center

Montefiore

npr wwdc

The U.S. surgeon general issues a stark warning about the state of youth mental health



PROTECTING YOUTH MENTAL HEALTH  
*The U.S. Surgeon General's Advisory*

American Academy of Pediatrics

Advocacy

Search AAP

### AAP-AACAP-CHA Declaration of a National Emergency in Child and Adolescent Mental Health

News / Advocacy / Child and Adolescent Health/Brain/Development / AAP-AACAP-CHA Declaration of a National Emergency in Child and Adolescent Mental Health

A declaration from the American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry and Children's Hospital Association



## National, State-by-State Data Show Depth of Mental Health Pandemic for Youth

POSTED AUGUST 8, 2022, BY THE ANNIE E. CASEY FOUNDATION



### COVID TRAUMA & LOSS

- 1 million people in US dead, 1,600 children
- >200,000 youth lost a primary caregiver
- **Dramatic** increases in incidence of youth reporting anxiety & depression

### Disparities

9% of all high schoolers attempted suicide

12% for Black students, 13% for students of two or more races and 26% for American Indian or Alaska Native high schoolers

23% of LGBTQ high schoolers reporting to have attempted suicide vs 6% of heterosexual youth.

Montefiore

PANDEMIC SURVEY

## Parents' Mental, Physical Health Impacted Since Start of Pandemic



say they could have used more emotional support than they received.




received treatment from a mental health professional.



were diagnosed with a mental health disorder since the pandemic started.

Mothers are more likely than fathers to say their mental health has worsened compared with before the pandemic (39% vs. 25%), but fathers are more likely to report behavioral and physical changes:

MOTHERS FATHERS



STRESS IN AMERICA™

© American Psychological Association

Montefiore



## The impact of COVID-19 on child and adolescent mental health and treatment considerations

Denise A. Chavira <sup>a,\*,</sup> Carolyn Ponting <sup>a, b,</sup> Giovanni Ramos <sup>a</sup>

[Show more](#)

Factors related to youth mental health risk and resilience during COVID-19?

**Individual** (e.g., age, gender, disability)

**Familial** (e.g., parent-child conflict, domestic violence)

**Community** (e.g., access to peers/teachers, learning environment)

**Social** (e.g., racism, economic status)

Montefiore

## Consider Youth Anxiety Disorders

- Quarantine/Lockdown
- Social Isolation
- Masks
- Anti-Science Messaging\*
- Health Risks
- Death
- Grief & Loss
- Family Isolation
- Economic impact



*YoungMinds reported that 83% of young respondents agreed that the pandemic worsened pre-existing mental health conditions, mainly due to school closures, loss of routine, and restricted social connections (YoungMinds, 2020).*

Montefiore





**EFFECTIVE CHILD THERAPY**  
Evidence-based mental health treatment for children and adolescents  
The services created by the Division of Clinical Child & Adolescent Psychology

SOCIETY OF CLINICAL CHILD & ADOLESCENT PSYCHOLOGY

Home | Concerns, Symptoms, & Disorders | Evidence-based Therapies | Tips & Tools

COVID-19 Information and Tips for Anxious Moms, Big and Little

**Evidence-based Approaches**  
Mental Health Information Based on the Best Available Science

FREE ASSESSMENT CENTER  
ADVICE FOR CHOOSING A PSYCHOLOGIST  
LEARN ABOUT EVIDENCE-BASED TREATMENT

Montefiore

# CBT for Youth Anxiety

A brief note on: CAMS Trial CAMELS

Study	N	Age Range	Diagnosis	Treatment Group	Comparison Group	Age Effect
Beautrais et al. (2002)	52	10-14	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Beautrais et al. (2005)	52	10-14	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2011)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2012)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2013)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2014)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2015)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2016)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2017)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2018)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2019)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2020)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2021)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2022)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2023)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2024)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction
Chen et al. (2025)	100	6-12	Anxiety	CBT (10 sessions)	Waitlist (10 sessions)	Age interaction


Kendall & Peterman, 2015



## The CAMS Trial Treatment Response

CGI-I = 1 or 2 ITT

**•COMB > CBT = SRT > PBO**




Montefiore

## Results From the Child/Adolescent Anxiety Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes

Golda S. Ginsburg, PhD, Emily M. Becker-Haimes, PhD, Courtney Keeton, PhD, Philip C. Kendall, PhD, ABPP, Satish Iyengar, PhD, Dara Sakolsky, MD, Anne Marie Albano, PhD, Tara Peris, PhD, Scott N. Compton, PhD, John Piacentini, PhD, ABPP

**FIGURE 3** Percent Remitters, Chronic, and Relapsers Across Follow-up Period



Note: CAMS Responder status associated with increased likelihood of group membership.

\* $p < .05$ .



Review > Curr Psychiatry Rep. 2018 Jul 28;20(8):65. doi: 10.1007/s11920-018-0924-9.

## Cognitive Behavioral Therapy for Childhood Anxiety Disorders: a Review of Recent Advances

Kelly N Banneyer<sup>1, 2</sup>, Liza Bonin<sup>3, 4</sup>, Karin Price<sup>3, 4</sup>, Wayne K Goodman<sup>5</sup>, Eric A Storch<sup>3, 4, 5</sup>

Affiliations + expand

PMID: 30056623 DOI: 10.1007/s11920-018-0924-9

Advances with respect to:

- Use of technology
- Increasing parental involvement

Montefiore

## Sundays at 9am?

 Springer Link

Open Access | Published: 18 September 2018

### Technology Delivered Interventions for Depression and Anxiety in Children and Adolescents: A Systematic Review and Meta-analysis

Rebecca Grist , Abigail Croker, Megan Denne & Paul Stallard

*Clinical Child and Family Psychology Review* 22, 147–171 (2019) | [Cite this article](#)

16k Accesses | 53 Citations | 11 Altmetric | [Metrics](#)

Montefiore



Behavior Therapy

Volume 52, Issue 5, September 2021, Pages 1171-1187



## Therapist-Led, Internet-Delivered Treatment for Early Child Social Anxiety: A Waitlist-Controlled Evaluation of the iCALM Telehealth Program ☆,

Jonathan S. Comer <sup>1</sup>, Jami M. Furr, Cristina del Buoto, Karina Silva, Natalie Hong, Bridget Pozzani, Amanita Sanchez, Danielle Comacchio, Aileen Herrera, Stefany Cox, Elizabeth Miguel, Christopher Georgiadis, Kristina Conroy, Anthony Puliafico

Show more

### Highlights

Limited options are broadly available for families seeking treatment for early child social anxiety.

The iCALM [Telehealth](#) Program uses videoconferencing to deliver therapist-led treatment for early child anxiety.

Outcomes of a waitlist-controlled examination of the iCALM Telehealth Program are presented.

iCALM led to improvements in child anxiety, impairment, and parental distress.

Families with high levels of parental accommodation may particularly benefit from iCALM.

Montefiore

## ARTICLES

<https://doi.org/10.1038/s41562-021-01235-0>

nature  
human behaviour



## A randomized trial of online single-session interventions for adolescent depression during COVID-19

Jessica L. Schleider <sup>1</sup>, Michael C. Mullarkey <sup>1</sup>, Kathryn R. Fox <sup>2</sup>, Mallory L. Dobias <sup>1</sup>, Akash Shroff <sup>1</sup>, Erica A. Hart <sup>2</sup> and Chantelle A. Roulston <sup>1</sup>

Montefiore



**ADAA** Anxiety & Depression Association of America  
Helping through shared treatment and education

FOR T

ABOUT ADAA NEWSLETTER SIGNUPS 501

UNDERSTAND ANXIETY & DEPRESSION FIND HELP EDUCATE

## ADAA Reviewed Mental Health Apps

Mental health apps can be effective in making therapy more accessible, efficient, and portable. Below are apps (listed alphabetically) that have been reviewed by ADAA members over the last few years. These volunteer reviewers are mental health professionals with degrees in psychology, medicine, social work, and counseling; they are not involved in the development or marketing of mobile apps.

### RATINGS KEY

<b>Ease of Use</b>	How easy is it to use the app?	1 = Very Difficult 5 = Very Easy
<b>Effectiveness</b>	How likely will the content grow or change over time to accommodate its audience?	1 = Highly Unlikely 5 = Highly Likely
<b>Personalization</b>	What is its ability to personalize individual needs?	1 = No Ability 5 = Complete Ability
<b>Interactive/Feedback</b>	How interactive is the app in giving feedback?	1 = Not Interactive 5 = Very Interactive
<b>Research Evidence</b>	Does scientific research demonstrate its effectiveness?	1 = No Research Evidence 5 = Appropriate Research Evidence

**Montefiore**

## Assess social media usage

Journal of Social and Clinical Psychology, 4, Vol. 27, No. 28

### No More FOMO: Limiting Social Media Decreases Loneliness and Depression

Marissa G. Hunt, Rachel Marsh, Courtney Lipson and Jordan Young

Published Online: December 2018 • <https://doi.org/10.13023/jscp.2018.07.10751>

PDF PDF PLUS

Share Tools

Journal of Social and Clinical Psychology

Volume 27 • Issue 10 • July 2018

**Montefiore**



## Resilience

- Decades of resilience research

- (Garmezy, Luthar, Rutter, Masten)

- Early trauma, SMI, extreme poverty & stress
  - Role of parent quality, family resources
  - Neurobiology, socioculture



*Resilience = process of positively adapting to (despite?) significant adversity* (see Luthar, 2003)

Montefiore



### The short list for resilience

- Capable caregiving and parenting
- Other close relationships
- Problem-solving skills
- Self-regulation skills
- Motivation to succeed
- Self-efficacy
- Faith, hope, belief life has meaning
- Effective schools or ECE
- Effective communities
- Effective cultural practices

Montefiore



## Parents: Overview... how many ways to say this?

- Parental mental health broadly tied to child mental health (see Ramchandani, 2003; Rutter, 1966)
- Parental stress IS THE MOST SIGNIFICANT predictor of child functioning during deployments, other disasters/adversity (e.g., Flake et al., 2009; LaGreca & Comer)
- A significant protective buffer for youth adjustment (war, disaster) is effective parenting & parent child-relationship (e.g., Papp et al., 2005)
  - Warmth (vs hostility), patience, self-compassion

Montefiore

## We must be Caregiver-Focused

- System-focus & Structural-focus
- Self-compassion/care
- Parent anxiety management
  - How do they manage stress?
  - Modeling feelings & coping
  - TOLERATE UNCERTAINTY



Montefiore



# Parents!



APA PsycArticles: Journal Article

## Cognitive-behavioral therapy for anxiety disordered youth: A randomized clinical trial evaluating child and family modalities.

© Request Permissions

Kendall, P. C., Hudson, J. L., Gosch, E., Flannery-Schroeder, E., & Suveg, C. (2008). Cognitive-behavioral therapy for anxiety disordered youth: A randomized clinical trial evaluating child and family modalities. *Journal of Consulting and Clinical Psychology, 76*(2), 282-297. <https://doi.org/10.1037/0022-006X.76.2.282>

The American Journal of  
**Psychiatry** Current Issue | Archive | About | Reprints/Journal | AP in Advance | Podcast | OER | Author Resources

[Back to table of contents](#)

[Previous Article](#) [Next Article](#)

Articles

[Full Access](#) [PDF](#)

### Preventing Onset of Anxiety Disorders in Offspring of Anxious Parents: A Randomized Controlled Trial of a Family-Based Intervention

Gold, S., Comburg, C., Ph.D., Kelly, L., Ph.D., Drake, P., Ph.D., Jennifer Tate, Ph.D., Rebecca Tenen, M.A., Mark A. Riddle, Ph.D.

Published Online: 25 Sep 2015 | <https://doi.org/10.1176/appi.ajp.2015.1491170>

Journal of the American Academy of Child & Adolescent Psychiatry  
Volume 54, Number 9, September 2015, Pages 1491-1497

Parent-Based Treatment as Efficacious as Cognitive-Behavioral Therapy for Childhood Anxiety: A Randomized Noninferiority Study of Supportive Parenting for Anxious Childhood Emotions

- Family accommodation
- Parent anxious behaviors
- Management of disruptive behaviors

Montefiore





## Assess family behaviors around communication



### HHS Public Access

Author manuscript

*J Clin Child Adolesc Psychol*. Author manuscript; available in PMC 2018 May 01.

Published in final edited form as:

*J Clin Child Adolesc Psychol*. 2017 ; 46(3): 331–342. doi:10.1080/15374416.2015.1063432.

### Event-related household discussions following the Boston Marathon bombing and associated posttraumatic stress among area youth

Aubrey L. Carpenter, M.A.<sup>1</sup>, R. Meredith Elkins, M.A.<sup>1</sup>, Caroline Kerns, M.A.<sup>1</sup>, Tommy Chou, M.A.<sup>2</sup>, Jennifer Greif Green, Ph.D.<sup>3</sup>, and Jonathan S. Comer, Ph.D.<sup>2</sup>

<sup>1</sup>Center for Anxiety and Related Disorders, Boston University, 648 Beacon Street, 6<sup>th</sup> Floor, Boston, MA, 02215

<sup>2</sup>Center for Children and Families, Florida International University, 11200 S.W. 8<sup>th</sup> Street, Miami, FL, 33199

<sup>3</sup>School of Education, Boston University, Two Silber Way, Boston, MA, 02215



Journal of the American Academy of  
CHILD & ADOLESCENT  
PSYCHIATRY

Journal of the American  
Academy of  
Child & Adolescent  
Psychiatry

NEW RESEARCH | ARTICLES IN PRESS

### Black Youth Suicide: Investigation of Current Trends and Precipitating Circumstances

Arielle H. Shattell, PhD ✉ Fatma Vakil, BS • Donna A. Ruch, PhD • Rhonda C. Boyd, PhD • Michael A. Lindsey, PhD • Jeffrey A. Bridge, PhD

Published: September 08, 2021 • DOI: <https://doi.org/10.1016/j.jaac.2021.08.021>

The New York Times

“What’s Going on With Our Black Girls?” Experts Warn of Rising Suicide Rates.

Illustration by a staff member of the New York Times.



© 2021 The New York Times





REVIEW

# Systematic Review: The Association Between Race-Related Stress and Trauma and Emotion Dysregulation in Youth of Color

Erika L. Roach, MA, Stephanie L. Haft, MA, Jingtong Huang, BA, Qing Zhou, PhD

**Objective:** This systematic review aims to summarize the current state of knowledge on the relations between race-related stress and trauma (RST) and emotion dysregulation, synthesize empirical research examining these associations in youth of color, and discuss clinical implications.

**Method:** We searched PubMed, ProQuest PsychInfo, and Web of Science for relevant articles on June 24, 2021. Eligible studies were empirical studies in peer-reviewed journals or from gray literature. They included a sample of participants (5-24 years of age) from racial and ethnic minority backgrounds and at least 1 measure of RST and emotion dysregulation. We evaluated target studies using the Quality Assessment for Diverse Studies and extracted information on associations between RST and emotion dysregulation, as well as mediators and moderators.

**Results:** Ultimately, 29 studies (78,173 participants) met inclusion criteria. A total of 28 studies were correlational, 16 were cross-sectional, and 12 were longitudinal. Greater RST was linked to greater emotion dysregulation in 78% of observed associations. Remaining associations were not significant. Relationships were mediated by types of coping, biological factors, and identity factors. RST was also related to several wellbeing outcomes through its relation with emotion dysregulation.

**Conclusion:** Results consistently demonstrated that greater exposure to RST is related to greater emotion dysregulation and decreased wellbeing in youth of color. These findings suggest that clinicians should incorporate the role of RST in case conceptualizations and treatment plans for this population. Future research should use multidimensional measures of RST and include experimental studies to examine the causal relationship between RST and emotion dysregulation.

**Keywords:** systematic review, racial stress, racial trauma, emotion dysregulation, youth

J Am Acad Child Adolesc Psychiatry 2022; ■(■): ■-■

Montefiore

## Does Racism Impact the Mental Health of Teenagers?



Danielle Fisher, B.S., Lillian Polanco-Roman, Ph.D., Catherine Ribaut, B.A., Brittany Klimsek, B.A., Melissa Sackis, Ph.D., Sandra Pimentel, Ph.D.

Department of Psychiatry and Behavioral Sciences, Montefiore Medical Center/Albert Einstein College of Medicine

**INTRODUCTION**

Racial/ethnic discrimination is a behavioral manifestation of racism that occurs on an interpersonal level every day. Discrimination is common in the lives of adolescents, and has been linked to psychiatric symptoms, particularly among racial/ethnic minority individuals. But this research is largely with adults.

Empirical research (e.g., the presence, intensity and persistence of emotional experiences) and emotion dysregulation have been implicated in youth mental health.

Very little is known about the relation between racial/ethnic discrimination and emotional distress.

The present study examined the relation among racism (i.e., racial/ethnic discrimination, psychiatric symptoms), depressive symptoms, irritability, somatization, suicidal ideation, emotion reactivity, and difficulties with regulating emotions.

**Hypothesis:** greater experiences of racial/ethnic discrimination would be positively associated with psychiatric symptoms, emotion reactivity, and emotion dysregulation.

**Psychiatric Distress**  
 Irritability  
 Somatization

**Emotion Reactivity**  
 Emotion Dysregulation

**METHODS**

**Sample:** Participants (n=22, 82% female) are adolescents at Ohio Dominican University Department Anxiety and Mood Program (ages 12-21 mean age 16.11-16.46, SD=1.85).

**Measures:**

- Experiences of Racism in Youth and Children (mean age, 2002)
- Difficulties with Emotion Regulation Scale (mean age, 2008)
- Beck Depression Inventory—Youth version (mean age, 2008)
- Autism Spectrum Questionnaire—Child version (mean age, 2008)
- Racial Identity Scale (mean age, 2008)
- Child PTSD Scale (mean age, 2008)

**Data Analysis:** Pearson correlation analyses. Data collection in 2019.

**Even experienced racial/ethnic discrimination in their lives:**

- 75% had someone inside a doll or something about their skin, ethnicity or language
- 69% had someone talking nasty to them
- 66% had someone tell them to stop because of the color of their skin, language, genetic features, or country of origin
- 66% had the racist insult/experience

**RESULTS**

Correlational analysis of racial/ethnic discrimination, emotion reactivity, emotion dysregulation, and psychiatric symptoms.

	1	2	3	4	5
1. Discrimination (Frequency)	22.72 (21.55)	-.04*	-.02*	-.03	-.04*
2. Emotion Reactivity	40.98 (22.38)	-.04*	-.05*	-.04*	-.04*
3. Emotion Dysregulation	23.75 (22.92)	-.04*	-.07*	-.05*	-.04*
4. Depressive Ideation	10.07 (21.98)	-.04*	-.04*	-.04*	-.04*
5. PTSD Scale	10.08 (22.18)	-.04*	-.04*	-.04*	-.04*
6. Suicidal ideation (SI)	22.27 (22.98)	-.04*	-.04*	-.04*	-.04*

\*p < .05. \*\*p < .01.

**CONCLUSION**

- Experiences of racial/ethnic discrimination are prevalent in our adolescent & emerging adult patient population.
- Increases in frequency of racial/ethnic discriminatory experiences associated with increases in emotion reactivity & SI.
- No sig. relation between discrimination and emotion dysregulation, depressive ideation, or PTSD symptoms.
- Findings broaden our understanding of how racial/ethnic discrimination may relate to, and possibly increase risk for, psychopathology among racial/ethnic minority youth.
- With the growing racial/ethnic minority youth population in the U.S., it is imperative that we better understand how racism may impact their mental health; thus, further research is warranted.
- Future research should examine whether discrimination increases emotion reactivity which in turn may increase risk for SI.
- Clinical Implications:** This information highlights the need to systematically assess for racism related experiences as part of clinical care.

**REFERENCES**

1. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Washington, DC: Author.

2. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

3. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

4. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

5. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

6. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

7. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

8. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

9. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

10. American Psychological Association. (2013). *Handbook of racial and ethnic disparities in mental health*. Washington, DC: Author.

### Can We Please Start Asking About Racism and Bias at the Doctor's Office?



Amanda Sheu, BA; Terresa Hsu-Walker, PhD; Miquelina Cerván, PhD

Montefiore Medical Center  
Bloom, NY

For more information, contact:  
Amanda Sheu, BA | amsheu@montefiore.org



SpringerBriefs in Psychology  
Advances in Child and Family Policy and Practice  
John P. Ackerman · Lisa M. Horowitz  
Editors

# Youth Suicide Prevention and Intervention

## Best Practices and Policy Implications

OPEN ACCESS Springer

### Utilizing Suicide Risk Screening as a Prevention Technique in Pediatric Medical Settings

[Annabelle M. Mounet](#), [Nathan J. Lowry](#) & [Lisa M. Horowitz](#)

Chapter | Open Access | First Online: 23 August 2022

254 Accesses | 2 Altmetric

Part of the [SpringerBriefs in Psychology](#) book series (ACFPP)

**75% of children and young people feel the future is frightening**  
Watch the panel discussion on a groundbreaking new study about climate anxiety, and join the live discussion below.

UAAQ How Climate Anxiety is Linked to Government Inaction | Global Study Launch  
Global launch event

## How youth climate anxiety is linked to government inaction

Tuesday 14 September 2021  
9-10 AM EST | 2-3 PM BST | 3-4 PM CEST  
ONLINE EVENT

The largest ever international survey of climate anxiety in children and young people

 <b>Caroline Hickman</b> Lead author of the study, psychotherapist. Watch on	 <b>Elisabeth Marks</b> Lead author of the study, clinical psychologist, Lecturer in Psychology, University of Bath	 <b>Luise Neubauer</b> German youth activist	 <b>Jennifer Uchendu</b> Nigerian youth activist	 <b>Elouise Mayall</b> British youth activist	 <b>Natasa Mavronicola</b> Human Rights expert at the University of Birmingham
---	---	--	--	---	--

Tweet #WofmTheFuture



AMERICAN PSYCHOLOGICAL ASSOCIATION

## Talking to kids about the war in Ukraine

Psychologists offer strategies for discussing the conflict in age appropriate ways with children and teens.

By Gary W. Lerner | December 16, 2022 | 8 min read

[Current Events](#) [Anxiety](#) [Child Development](#) [Teens](#)



**RECOMMENDED READING**

- CHILD CARE'S BOOK: What Boys Do \$16.99
- CHILDREN'S BOOK: My Emotions \$12.99
- CHILD CARE'S BOOK: Emily Hooper and the Fairy Report \$16.99

Montefiore

Wiley Online Library

Search



Login / Register

Depression & Anxiety

ADAA  
Anxiety & Depression  
Association of America

Depression & Anxiety

Volume 20, Issue 4  
2004  
Pages 155-164

Research Article

### Child anxiety in primary care: Prevalent but untreated

Denise A. Chavira Ph.D., Murray B. Stein M.D., M.P.H., Kelly Bailey M.A., Martin T. Stein M.D.

First published: 10 January 2005 | <https://doi.org/10.1002/da.20039> | Lifespan: 260

PDF TOOLS SHARE

Abstract

WILEY

Would you like to be a guest editor for a special issue?

Montefiore




Research

JAMA Psychiatry | Original Investigation

## Brief Behavioral Therapy for Pediatric Anxiety and Depression in Primary Care: A Randomized Clinical Trial


Richard Steingard, PhD; David N. Evans, MD; Miranda S. Roseman, PhD; Anjali Gonzalez, PhD; Megan McPherson, PhD; Jeffrey D. Gadow, PhD; Fakhri L. Lavee, PhD; Deborah Pincus, MD; Sarah Langley, PhD

Figure 2. Response (Clinical Global Impression-Improvement Score [2] at Week 16 to Brief Behavioral Therapy [BBT] and Assisted Referral to Care [ARC] for Total Sample and by Hispanic Ethnicity



Error bars indicate 95% CIs.  
 \* $P < .001$  for comparison of BBT and ARC.  
 \*\* $P = .04$  for comparison of BBT and ARC.

Figure 3. Pediatric Anxiety Rating Scale (PARS), Children's Depression Rating Scale-Revised (CDRS-RI), and Children's Global Adjustment Scale (CGAS) Scores by Arm From Baseline to Week 16



ARC, values added referral to care; BBT, brief behavioral therapy. Error bars indicate 95% CIs.

Montefiore

### What steps to take? How to approach concerning anxiety in youth.

EXPORT Add To My List Request Permissions Database: APA PsycArticles Journal Article

Kendall, Philip C., Makover, Heather, Swan, Anna, Carper, Matthew M., Mercado, Roger, Kagan, Eliana, Crawford, Erka

#### Citation

Kendall, P. C., Makover, H., Swan, A., Carper, M. M., Mercado, R., Kagan, E., & Crawford, E. (2016). What steps to take? How to approach concerning anxiety in youth. *Clinical Psychology: Science and Practice*, 23(3), 211-229. <https://doi.org/10.1111/cpsp.12156>

SEARCH BROWSE Recent Sources My List My Playlist

#### Pediatric primary care as a stepped care setting for youth anxiety: Commentary on "What steps to take? How to approach concerning anxiety in youth".

EXPORT Add To My List Request Permissions Database: APA PsycArticles Comment Reply

Rosenman, Miriam, Pincus, Deborah

#### Citation

Rosenman, M., & Pincus, D. (2016). Pediatric primary care as a stepped care setting for youth anxiety: Commentary on "What steps to take? How to approach concerning anxiety in youth". *Clinical Psychology: Science and Practice*, 23(3), 230-232. <https://doi.org/10.1111/cpsp.12157>

Clinical Psychology: Science and Practice  
 Journal TOC

Get Access

ore



<https://www.theatlantic.com/video/index/609958/pandemic-kids/>

Montefiore

## Developmental vulnerability: Emerging adults

Becoming an Emerging Adult at Montefiore (BEAM) invites you to



**BRONX TEEN & YOUNG ADULT  
VIRTUAL TOWN HALL**

Montefiore Health System and the  
Bronx Teen & Young Adult Virtual Town Hall

Bronx Youth, ages 16-25, are invited to engage in an open discussion about coping with current issues such as:

- What school will look like in the Fall with the ongoing pandemic
- Transitioning to virtual learning and dealing with social disconnection
- Coping with the ongoing stresses of racism
- Establishing independence while living with family

All are welcome to hear how other teens or young adults are coping with these issues.

**Becoming an Emerging Adult at Montefiore (BEAM)**

Montefiore



Notice the  
BEST part.

## The Atlantic

HOMEROOM

# Homeroom: The Pandemic's Potential Silver Lining for Kids

Each child will process this time differently, and adults can help kids find opportunity in the life that awaits them.

By Abby Freireich and Brian Platzer

Montefiore

## Hope & Gratitude


“Hope is a discipline”

– Youth anxiety & Self-efficacy

– *Thank You*

– *Obrigado*

– *Gracias*

Sandra S. Pimentel  
[spimente@montefiore.org](mailto:spimente@montefiore.org)  
[@SandraPimPhD](https://twitter.com/SandraPimPhD) 



Montefiore YES Garden

Montefiore



# STIGMA OF MENTAL ILLNESS

Fernando T. Taveras, M.D.  
Assistant Clinical Professor of Psychiatry.  
Psychiatrist/Addiction Specialist.  
SOMOS IPA/FTMDPC/CMD/MIH/NYPH.

October 6, 2022

## Purpose and Objectives

### PURPOSE

To create an impact in the medical community regarding the stigma of mental illness.

### OBJECTIVES

- Clarify the concept of mental illness stigma
- Develop awareness and concern of mental illness stigma
- Discuss consequences of stigma
- Take action

### FINANCIAL DISCLOSURE

*None*





**You are NOT ALONE**

Millions of people are affected by mental illness each year. Across the country, many people just like you work, perform, create, compete, laugh, love and inspire every day.

 1 in 5 U.S. adults experience mental illness	<b>1 in 20</b> 1 in 20 U.S. adults experience serious mental illness	<b>17%</b> of youth (6-17 years) experience a mental health disorder
---	---	---

- [1 in 5](#) U.S. adults experience mental illness each year
- [1 in 20](#) U.S. adults experience serious mental illness each year
- [1 in 6](#) U.S. youth aged 6-17 experience a mental health disorder each year
- [50%](#) of all lifetime mental illness begins by age 14, and 75% by age 24
- Suicide is the [2nd leading](#) cause of death among people aged 10-34



**2020**  
**Mental Health  
By the Numbers**

**RECOGNIZING THE IMPACT**

2020 was a year of challenges, marked by loss and the uncertainty of the COVID-19 pandemic.

We must recognize the significant impact of the pandemic on our mental health – and the importance of increasing access to timely and effective care for those who need it.

**2020 was a year of challenges**, marked by loss and the uncertainty of the COVID-19 pandemic.

We must recognize the significant impact of the pandemic on our mental health—and the importance of increasing access to timely and effective care for those who need it.

- [1 in 15](#) U.S adults experienced both a substance use disorder and mental illness
- [12+ million](#) U.S adults had serious thoughts of suicide
- [1 in 5](#) U.S adults report that the pandemic had a significant negative impact on their mental health
  - [45%](#) of those with mental illness
  - [55%](#) of those with serious mental illness
- Among people aged 12 and older who drink alcohol, [15%](#) report increased drinking
- Among people aged 12 and older who use drugs, [10%](#) report increased use
- Among U.S. adults who received mental health services:
  - [17.7 million](#) experienced delays or cancellations in appointments
  - [7.3 million](#) experienced delays in getting prescriptions
  - [4.9 million](#) were unable to access needed care
- [26.3 million](#) U.S adults received virtual mental health services in the past year
  - [34%](#) of those with mental illness
  - [50%](#) of those with serious mental illness



# Stigma

Refers to the prejudice and discrimination associated with the conditions that are enacted through social relationships and that devalue the person's humanity.

Different types of stigma:

1. Public
2. Self
3. Structural

---

<https://onlinelibrary.wiley.com/doi/full/10.1002/9781118410868.wbehibs082>

# Public Stigma

- The process in which individuals in the general population first endorse the stereotypes of mental illness and then act in a discriminatory manner.
- Comprises reactions of the general public towards a group based on stigma about that group.
- It is further important to note that labeling often implies a separation of 'us' from 'them'.

This separation easily leads to the belief that 'they' are fundamentally different from 'us' and that 'they' even *are* the thing they are labelled.

---

<https://onlinelibrary.wiley.com/doi/full/10.1002/9781118410868.wbehibs082>



- **Stereotypes** are knowledge structures known to most members of a social group. Quickly generate impressions and expectations of persons who belong to a stereotyped group. People do not necessarily agree with the stereotypes they are aware of.
- **Prejudice** endorses these negative stereotypes (“That’s right! All persons with mental illness are violent”) and have negative emotional reactions as a consequence (“They all scare me”).
- **Discrimination**, making a negative remark about patient’s mental illness or treatment.

---

<https://www.cambridge.org/core/journals/european-psychiatry/article/mental-illness-stigma-concepts-consequences-and-initiatives-to-reduce-stigma/3AE7283F0F35980994B4BD71E92C3C08>

- Prejudice leads to discrimination as a behavioral reaction, yields anger that can lead to hostile behavior.
- Mental illness, angry prejudice may lead to withholding help or replacing health care with the criminal justice system.
- This association between perceived dangerousness of persons with mental illness, fear, and increased social distance has been validated for different countries, including Germany.
- Social, economic and political power is necessary to stigmatize.

---

<https://www.cambridge.org/core/journals/european-psychiatry/article/mental-illness-stigma-concepts-consequences-and-initiatives-to-reduce-stigma/3AE7283F0F35980994B4BD71E92C3C08>



## Self Stigma

- The process in which a person with mental illness internalizes prejudice and discrimination that results from public stigma.
- Refers to the reactions of individuals who belong to a stigmatized group and turn the stigmatizing attitudes against themselves.
- Comprises of stereotyping, prejudice and discrimination.
- Self-prejudice leads to negative emotional reactions.
- Behavior responses
- Self-discriminating behavior

<https://scitechconnect.elsevier.com/wp-content/uploads/2015/09/The-Stigma-of-Mental-Illness.pdf>

## Structural Stigma

1. The policies of private and governmental institutions that intentionally restrict the opportunities of people with mental illness.
2. The policies of institutions that yield unintended consequences that limit options for people with mental illness.
3. Criminality and mental illness.

<https://scitechconnect.elsevier.com/wp-content/uploads/2015/09/The-Stigma-of-Mental-Illness.pdf>



## Stigma in providers of medical care

- Somatic SxS are excessively attributed to mental illness.
- Frustration due to inadequate compliance.
- Fear of potential violence may limit full evaluation of the patient.
- Some health insurance doesn't adequately cover mental illness treatment.



## The Consequences of stigma

- Reluctance to seek help or treatment
- Lack of understanding by family, friends, co-workers or others
- Fewer opportunities for work, school or social activities or trouble finding housing
- Bullying, physical violence or harassment
- **Health insurance** that doesn't adequately cover your mental illness treatment
- The belief that they will never succeed at certain challenges or that they can't improve their situation



- Public stigma results in everyday-life discrimination encountered.
- Structural discrimination includes private and public institutions that intentionally or unintentionally restrict opportunities of persons with mental illness.
- Self-stigma/empowerment and fear of stigma as a reason to avoid treatment.

<https://www.cambridge.org/core/journals/european-psychiatry/article/mental-illness-stigma-concepts-consequences-and-initiatives-to-reduce-stigma/3AE7283F0F35980994B4BD71E92C3C08>







Psychiatric symptoms and life disabilities of many persons living with mental illness can be significantly improved by various psychiatric and psychosocial treatments.

Case ML.

<https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/stigma-of-mental-illness-and-ways-of-diminishing-it/EF630432A797A5296D131EC0D4D5D7AD#B1>

## Ways to reduce the stigma towards mental illness



# Education!!

- Educating the public, and medical providers
- Review our own view of mental illness
- Share real life examples
- Provide pamphlets
- Educational material/NAMI
- Maintain close relationship with the mental health provider



## Summary

- Stigma refers to the prejudice and discrimination associated with the conditions that are enacted through social relationships and that devalue the person's humanity.
- Three types are recognize: self, public, and structural.
- Stigma can negatively impact appropriate medical health services.
- Stigma results in everyday-life discrimination encountered, intentionally or unintentionally and restrict opportunities of persons with mental illness.
- Education

23





## Contact Information

Name: Fernando T. Taveras.

Title: Assistant Clinical professor of Psychiatry.

Organization Somos  
IPA/FTMDPC/MIH/CMD/NYPH.

Email [ftaveras@ftmdpc.com](mailto:ftaveras@ftmdpc.com)

Phone 212-543-3500.



*Thank  
you*





Mild Cognitive Impairment

# Something is not right with my brain

October 6, 2022



## Purpose and Objectives

**PURPOSE** *Update on Mild Cognitive Impairment (MCI)*

**OBJECTIVES**

- Understand the continuum of cognitive decline
- Recognize MCI and its trajectory
- Discuss possible treatment options
- Recognize the implications of MCI

**FINANCIAL DISCLOSURE** *None*





## Agenda

- Case presentation
- What is MCI and how to diagnose it
- Types and trajectory of MCI
- Disease treatment and patient treatment
- Impact on chronic disease management
- Take home points

## George Hennawi, MD, CMD, FACP

- Senior Director of the Centers for Successful Aging
- Chair of Geriatrics at MedStar Good Samaritan and MedStar Union Memorial Hospitals
- Physician Executive Director of Geriatrics and Senior Services, MedStar Health
- [george.hennawi@medstar.net](mailto:george.hennawi@medstar.net)



## Clinical Case

- 70 yo psychologist presents with memory problems.
- PCP is concerned about the patient's ability to organize and follow information.
- The patient arrived at the Center 45 minutes late and reported that she did not know she had an appointment.
- She forgot to bring the list of her medications.
- She reports a fall without a brain bleed in 2020 and since then she has been having trouble with word retrieval. She is very worried about her memory, "my brain is foggy".
- Few weeks ago, she was in California, and she hit a median while driving and she drove in the middle of the night to find someone to fix the tires.



## Clinical Case

- She has been scheduled to have multiple tests and she could not figure out how to schedule the appointments.
- She continues to work full time and has been managing all her finances, this was confirmed by her husband.
- He reports that she has been having issues with problem solving and time management.
- Less initiative in organizing the house.
- This has progressed over the past year or little more.





## What is the next step in the evaluation?

- A- Order a CT scan of the head to rule out consequences of the fall and head trauma
- B- Refer to your local psychiatrist
- C- Patient is non-compliant, establish a relationship contract
- D- Perform a comprehensive assessment including COVID history

## What is the next step in the evaluation?

- A- Order a CT scan of the head to rule out consequences of the fall and head trauma
- B- Refer to your local psychiatrist
- C- Patient is non-compliant, establish a relationship contract
- **D- Perform a comprehensive assessment including COVID history**



## Comprehensive Assessment

- H&P (sleep disorders, head trauma, COVID history, timeframe)
- Thorough medication review (anticholinergics)
- Cognitive assessment
- Functional evaluation
- Psychiatric and mental health assessment
- Neurological exam
- Social assessment
- Lab work (TSH, B12, Folate, CBC, BMP, HIV, RPR)

## Tools for your assessment

### Cognitive evaluation

- Mini-Cog
- MMSE
- MoCA
- SLUMS
- Formal Neuropsychiatric evaluation

### Mood and function

- Geriatric Depression Screen
- PHQ9
- KATZ ADLs/IADLs



MONTREAL COGNITIVE ASSESSMENT (MOCA) Version 7.1 Original Version		Education : Sex :	Date of birth : DATE :	POINTS
<b>VISUOSPATIAL / EXECUTIVE</b>		Copy cube	Draw CLOCK (Ten past eleven) (3 points)	
 [ ]	 [ ]	[ ]	[ ]	[ ]
<b>NAMING</b>				
 [ ]	 [ ]	 [ ]		/3

## Back to our patient

- HTN, Hyperlipidemia, Depression, UI, insomnia, head trauma in 2020
- Medication list includes: Aspirin, Fluoxetine, Lisinopril, Oxybutynin, Atorvastatin, Cetirizine, Benadryl
- Her MoCA is 27/30 with deficit in short term recall (3/5) and executive function (TMT)
- Her KATZ ADL and IADL are both intact
- Her depression screen is positive
- No focal deficit on exam
- Lab work is within normal limits



## What do you tell this patient ?

- A-This is part of the expected change that happen with normal aging
- B-Your assessment meets the criteria for dementia Alzheimer's type
- C-We need to reduce your medications and improve your sleep and mood
- D-Your MoCA is within the normal range, no concerns about cognitive issues

## What do you tell this patient ?

- A-This is part of the expected change that happen with normal aging
- B-Your assessment meets the criteria for dementia Alzheimer's type
- C-We need to reduce your medications and improve on your sleep and mood
- D-Your MoCA is within the normal range, no concerns about cognitive issues



## The Continuum



## What is the diagnosis?

Mild Cognitive Impairment (MCI)



## MCI

- MCI as a syndrome refers to cognitive impairment that does not meet the criteria for dementia but is more than normal aging
- Objective evidence of impairment in cognition with preservation of independence and no evidence of significant impairment in social or occupational functioning
- Incidence: Age 60 to 64 years: 6.7 percent, age 80-84 years is 25 percent

## Back to our patient

- Discuss the diagnosis of MCI
- Fluoxetine reduced, Oxybutynin reduced and stopped.
- Stopped Benadryl and Cetirizine
- Escitalopram started
- Sleep study was done and normal
- Return 6 months later, feeling better emotionally, but has missed several doctor's appointment lost interest in cooking
- Her repeat MoCA is 26/30 with no changes



## What are my chances of developing Dementia?

- A- MCI does not progress to dementia
- B- MCI progress to dementia at a rate of 15% per year
- C- All patients with MCI develop Alzheimer's disease within 6 years.
- D- With MCI there are no chances reversibility

## What are my chances of developing Dementia?

- A- MCI does not progress to dementia
- B- MCI progress to dementia at a rate of 15% per year
- C- All patients with MCI develop Alzheimer's disease within 6 years.
- D- With MCI there are no chances reversibility



## Types of Mild Cognitive Impairment

### Amnestic

- Involves memory mainly
- Memory complaint, preferably corroborated by an informant
- Objective memory impairment (for age and education)
- Thought to be a precursor of AD



MedStar Health

### Non-Amnestic

- impairment in a single or multiple **nonmemory** domains.
- Domains such as executive functioning, language, or visual spatial skills
- Objective impairment in those domains
- It can be a precursor for Vasc-D, FTD, DLB.

Geriatrics and Senior Services 21

## Trajectory

- Studies showed that MCI (amnestic type) progress to AD at 15% per year and 80% of patients have converted to AD in 6 years
- MCI with isolated executive dysfunction is associated with vascular disease and a predictor of vascular dementia
- MCI with multiple domains can progress to other type of neurocognitive disorders
- Reported reversibility in some cases

⋮



MedStar Health

Geriatrics and Senior Services 22





## Next Step

- Patient is interested in doing everything she can to prevent Alzheimer's
- She wants to plan her life proactively.
- She is also interested in enrolling in trials of the new Alzheimer's medications

## Which of the following has shown statistically significant delay into the progression toward Dementia?

- A-Donepezil
- B-Memantine
- C-Ginkgo-Biloba
- D-Turmeric
- E-None of the above



## Which of the following has shown statistically significant delay into the progression toward Dementia?

- A-Donepezil
- B-Memantine
- C-Ginkgo-Biloba
- D-Turmeric
- E-None of the above

## Treatment of the disease

- No drug therapy have been proven effective
- Ch-I, do not decrease the risk of conversion to Dementia
- Memantine is not recommended
- Ginkgo-Biloba, Turmeric, limited efficacy data
- Cocoa (small study)
- Testosterone
- Anti Amyloid therapy: Aducanumab, Lecanemab, Donanemab, Gantenerumab



## A local institution is participating in a trial for Aducanumab, what test is needed to qualify?

- A- CT scan of the head
- B- Functional MRI
- C- PET Amyloid imaging
- D- PET FDG Scan
- E- None of the above

## A local institution is participating in a trial for Aducanumab, what test is needed to qualify?

- A-CT scan of the head
- B- Functional MRI
- **C-PET Amyloid imaging**
- D- PET FDG Scan
- E-None of the above



## Role of Neuroimaging

No recommendation in routine assessment


MRI/CT to rule out subdural hematoma, NPH etc..

Structural MRI can show loss of volume of the hippocampus

FDG PET


Amyloid/Tau PET

## Results of the PET Amyloid





# MRI of the Brain




# Treat the patient

-  Exercise
-  Diet
-  Socialization
-  Modification of vascular risk factors
-  Support and commitment to being there for her
-  Regular evaluation for changes



## Implications



## Take home points

- MCI is part of a continuum of cognitive decline
- Majority of cases develop into Dementia, not always Alzheimer's
- There is no available disease treatment
- Focus on treating the patient
- Be aware of the implications on safety, legal issues and treatment of chronic diseases



Questions?

It's how we **treat people.**



Thank you

It's how we **treat people.**



Thank you for attending “Advancing Community Health and Well-being by Addressing Inequity in the Practice of Medicine,” provided by Healthfirst, SOMOS Community Care, and Albert Einstein College of Medicine – Montefiore Medical Center.

## **COURSE DIRECTORS**

Susan J. Beane, MD, FACP  
*Executive Medical Director*  
*Healthfirst*

Allison Stark, MD, MBA  
*Vice President and Chief Medical Officer*  
*CMO Montefiore Care Management*  
*Assistant Professor of Medicine (Geriatrics)*  
*and Family & Social Medicine*  
*(Palliative Care) Albert Einstein College of*  
*Medicine*

## **PLANNING COMMITTEE**

Victor B. Hatcher, PhD-Peer Reviewer  
*Associate Dean*  
*Albert Einstein College of Medicine*  
*Montefiore Medical Center*

Elizabeth J. Jean-Jacques, MPA  
*Assistant Vice President, Medical*  
*Optimization*  
*Healthfirst*

Angela Sullivan, MPH  
*Manager, Provider Education*  
*Healthfirst*

Melisa Damcevska, MPH, CHES  
*Project Specialist, Provider Education*  
*Healthfirst*

Raymond Thornhill  
*Senior Community Engagement Manager*  
*Healthfirst*

Lidia Virgil  
*Chief Operations Officer*  
*SOMOS Community Care*

## **FACULTY**

LaPrincess Brewer, MD, MPH, FACC, FACP, FASPC

Enrique Ruiz Escudero

Bernard Fialkoff, DDS

Douglas G. Fish, MD

George Hennawi, MD

Arthur Klein, MD, BSMD

Alyson K. Myers, MD

Mara Minguez, MD, MSc

Andrey Ostrovsky, MD, FAAP

Yomaris Peña, MD

Errol Pierre, MPA, DBA

Sandra S. Pimentel, PhD

Fernando Taveras, MD



---

## About Healthfirst

Healthfirst is New York's largest not-for-profit health insurer, earning the trust of 1.8 million members by offering access to affordable healthcare. Sponsored by New York City's leading hospitals, Healthfirst's unique advantage is rooted in its mission to put members first by working closely with its broad network of providers on shared goals. Healthfirst takes pride in being pioneers of the value-based care model, recognized as a national best practice. For nearly 30 years, Healthfirst has built its reputation in the community for top-quality products and services New Yorkers can depend on. It has grown significantly to serve the needs of members, offering market-leading products to fit every life stage, including Medicaid plans, Medicare Advantage plans, long-term care plans, qualified health plans, and individual and small group plans. Healthfirst serves members in New York City and on Long Island, as well as in Westchester, Sullivan, and Orange counties.

For more information on Healthfirst, visit [healthfirst.org](https://www.healthfirst.org)

## About SOMOS

SOMOS is a non-profit, physician-led network of over 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City. Launched in 2015 by its Chairman Dr. Ramon Tallaj, SOMOS is the largest and only physician-led performance provider system participating in the New York State Delivery System Reform Incentive Payment Program (DSRIP). The SOMOS network includes providers delivering culturally competent care to patients in some of New York City's most vulnerable populations, particularly Latino, Asian, African-American and immigrant communities throughout the Bronx, Brooklyn, Manhattan and Queens.

## About Albert Einstein College of Medicine — Montefiore Medical Center

The mission of Montefiore is to heal, to teach, to discover and to advance the health of the communities we serve. From its beginning in 1884, as a facility for the care of patients with tuberculosis and other chronic illnesses, to the new millennium, Montefiore has been at the forefront of patient care, research and education and steadfast commitment to its community. As the academic medical center and University Hospital for Albert Einstein College of Medicine, Montefiore Medical Center is nationally recognized for clinical excellence—breaking new ground in research, training the next generation of healthcare leaders, and delivering science-driven, patient-centered care.

Montefiore's partnership with Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Together, the two institutions are among 38 academic medical centers nationwide to be awarded a prestigious Clinical and Translational Science Award (CTSA) by the National Institutes of Health. At the intersection of Einstein science and Montefiore medicine is our commitment to scientific inquiry. This commitment has resulted in the creation of the Montefiore-Einstein Centers of

---

Excellence in cancer care, cardiovascular services, transplantation and children's health, where nationally recognized investigators and multidisciplinary clinical teams collaborate to develop and deliver advanced, innovative care.

The second-largest medical residency program in the country, with 1,251 residents and fellows across 89 programs, Montefiore provides the doctors of tomorrow a unique opportunity for education and training in one of the most diverse urban areas in the country – one where the population is global, the disease burden is high, and the need for quality care is great. The partnership is further strengthened by the dual appointments of faculty and physicians across both organizations—enhancing synergies and collaborations for research, teaching and patient care.



Thank you for attending  
“Advancing Community Health and Well-being by Addressing Inequity in  
the Practice of Medicine”



Healthfirst is the brand name used for products and services provided by one or more of the Healthfirst group of affiliated companies.

© 2022 HF Management Services, LLC

1307-22